<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1283" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1283/" /><meta name="ncbi_pagename" content="Primary Hyperoxaluria Type 1 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Primary Hyperoxaluria Type 1 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Primary Hyperoxaluria Type 1" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/11/30" /><meta name="citation_author" content="Dawn S Milliner" /><meta name="citation_author" content="Peter C Harris" /><meta name="citation_author" content="Andrea G Cogal" /><meta name="citation_author" content="John C Lieske" /><meta name="citation_pmid" content="20301460" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1283/" /><meta name="citation_keywords" content="Alanine-glyoxylate transaminase" /><meta name="citation_keywords" content="AGXT" /><meta name="citation_keywords" content="Primary Hyperoxaluria Type 1" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Primary Hyperoxaluria Type 1" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Dawn S Milliner" /><meta name="DC.Contributor" content="Peter C Harris" /><meta name="DC.Contributor" content="Andrea G Cogal" /><meta name="DC.Contributor" content="John C Lieske" /><meta name="DC.Date" content="2017/11/30" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1283/" /><meta name="description" content="Primary hyperoxaluria type 1 (PH1) is caused by a deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is absent, glyoxylate is converted to oxalate, which forms insoluble calcium oxalate crystals that accumulate in the kidney and other organs. Individuals with PH1 are at risk for recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), or end-stage renal disease (ESRD). Age at onset of symptoms ranges from infancy to the sixth decade. Approximately 10% of affected individuals present in infancy or early childhood with nephrocalcinosis, with or without nephrolithiasis, and failure to thrive related to renal failure. The majority of individuals with PH1 present in childhood or early adolescence, usually with symptomatic nephrolithiasis and normal or reduced kidney function. The remainder of affected individuals present in adulthood with recurrent renal stones and a mild-to-moderate reduction in kidney function. The natural history of untreated PH1 is one of progressive decline in renal function as a result of calcium oxalate deposits in kidney tissue and complications of nephrolithiasis (e.g., obstruction and infection) with eventual progression to oxalosis (widespread tissue deposition of calcium oxalate) and death from ESRD and/or complications of oxalosis." /><meta name="og:title" content="Primary Hyperoxaluria Type 1" /><meta name="og:type" content="book" /><meta name="og:description" content="Primary hyperoxaluria type 1 (PH1) is caused by a deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is absent, glyoxylate is converted to oxalate, which forms insoluble calcium oxalate crystals that accumulate in the kidney and other organs. Individuals with PH1 are at risk for recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), or end-stage renal disease (ESRD). Age at onset of symptoms ranges from infancy to the sixth decade. Approximately 10% of affected individuals present in infancy or early childhood with nephrocalcinosis, with or without nephrolithiasis, and failure to thrive related to renal failure. The majority of individuals with PH1 present in childhood or early adolescence, usually with symptomatic nephrolithiasis and normal or reduced kidney function. The remainder of affected individuals present in adulthood with recurrent renal stones and a mild-to-moderate reduction in kidney function. The natural history of untreated PH1 is one of progressive decline in renal function as a result of calcium oxalate deposits in kidney tissue and complications of nephrolithiasis (e.g., obstruction and infection) with eventual progression to oxalosis (widespread tissue deposition of calcium oxalate) and death from ESRD and/or complications of oxalosis." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1283/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ph1/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1283/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE893893E040873100000000081C038A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1283_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1283_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bgc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ph2/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1283_"><span class="title" itemprop="name">Primary Hyperoxaluria Type 1</span></h1><p class="contrib-group"><span itemprop="author">Dawn S Milliner</span>, MD, <span itemprop="author">Peter C Harris</span>, PhD, <span itemprop="author">Andrea G Cogal</span>, BS, and <span itemprop="author">John C Lieske</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1283_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1283_ai__"><div class="contrib half_rhythm"><span itemprop="author">Dawn S Milliner</span>, MD<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@nwad.renillim" class="oemail">ude.oyam@nwad.renillim</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Peter C Harris</span>, PhD<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@retep.sirrah" class="oemail">ude.oyam@retep.sirrah</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Andrea G Cogal</span>, BS<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@aerdna.lagoc" class="oemail">ude.oyam@aerdna.lagoc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John C Lieske</span>, MD<div class="affiliation small">Mayo Clinic<br />Rochester, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.oyam@nhoj.ekseil" class="oemail">ude.oyam@nhoj.ekseil</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 19, 2002</span>; Last Update: <span itemprop="dateModified">November 30, 2017</span>.</p><p><em>Estimated reading time: 56 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ph1.Summary" itemprop="description"><h2 id="_ph1_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Primary hyperoxaluria type 1 (PH1) is caused by a deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), which catalyzes the conversion of glyoxylate to glycine. When AGT activity is absent, glyoxylate is converted to oxalate, which forms insoluble calcium oxalate crystals that accumulate in the kidney and other organs. Individuals with PH1 are at risk for recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), or end-stage renal disease (ESRD). Age at onset of symptoms ranges from infancy to the sixth decade. Approximately 10% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals present in infancy or early childhood with nephrocalcinosis, with or without nephrolithiasis, and failure to thrive related to renal failure. The majority of individuals with PH1 present in childhood or early adolescence, usually with symptomatic nephrolithiasis and normal or reduced kidney function. The remainder of affected individuals present in adulthood with recurrent renal stones and a mild-to-moderate reduction in kidney function. The natural history of untreated PH1 is one of progressive decline in renal function as a result of calcium oxalate deposits in kidney tissue and complications of nephrolithiasis (e.g., obstruction and infection) with eventual progression to oxalosis (widespread tissue deposition of calcium oxalate) and death from ESRD and/or complications of oxalosis.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of PH1 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with hyperoxaluria or hyperoxalemia by identification <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>AGXT</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Failure to identify at least one <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should prompt examination for other types of primary hyperoxaluria and in occasional circumstances may require consideration of liver biopsy to assay the activity of the enzyme alanine:glyoxylate-aminotransferase (AGT). However, given the wide availability of genetic testing, liver biopsy to obtain tissue for enzymatic activity is now rarely employed.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Reduction of calcium oxalate supersaturation in the urine to minimize stone formation; reduction of calcium oxalate supersaturation in the plasma in individuals with ESRD to minimize systemic deposition of calcium oxalate crystals; treatment of kidney stones; reduction of oxalate biosynthesis; dialysis; organ transplantation as either liver transplantation or combined liver/kidney transplantation.</p><p><i>Prevention of primary manifestations:</i> To reduce calcium oxalate supersaturation in the urine: maintenance of high fluid intake; inhibition of calcium oxalate crystal formation with potassium or sodium citrate, pyrophosphate-containing solutions. To reduce oxalate biosynthesis: pyridoxine supplements for those who are pyridoxine responsive.</p><p><i>Surveillance:</i> At regular intervals, obtain serum creatinine to estimate glomerular filtration rate (GFR), renal ultrasound examinations or other kidney imaging, urinalysis; and periodic fundoscopic eye examinations. Additionally:</p><ul><li class="half_rhythm"><div>In those with reduced GFR (&#x0003c;60 mL/min/1.73 m<sup>2</sup>): regular measurement of plasma oxalate and more frequent monitoring of kidney function.</div></li><li class="half_rhythm"><div>In individuals with greatly reduced GFR (&#x0003c;30 mL/min/1.73 m<sup>2</sup>) or rapid deterioration in function: frequent assessment of serum creatinine and plasma oxalate. At regular intervals obtain x-ray examination of the long bones, electrocardiogram for conduction abnormalities, echocardiogram for evidence of oxalate cardiomyopathy, hemoglobin, thyroid function testing, and frequent clinical evaluation for additional complications of oxalosis.</div></li></ul><p><i>Agents/circumstances to avoid:</i> Dehydration from any cause can lead to irreversible kidney failure and should be strictly avoided. Individuals with PH1 should avoid intake of vitamin C that exceeds the recommended daily allowance, loop diuretics, high doses of nonsteroidal anti-inflammatory medications or other medications that can compromise kidney function; and large intake of foods high in oxalate (e.g., chocolate, rhubarb, starfruit).</p><p><i>Evaluation of relatives at risk:</i> Early diagnosis of at-risk relatives enables early institution of treatment and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PH1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with PH1 has a 25% risk of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% risk of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% risk of being unaffected and not a carrier. Carrier testing for at-risk relatives and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if both pathogenic variants have been identified in a family. Assay of AGT enzymatic activity prenatally is not generally offered because it requires a fetal liver biopsy.</p></div></div><div id="ph1.Diagnosis"><h2 id="_ph1_Diagnosis_">Diagnosis</h2><div id="ph1.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Primary hyperoxaluria type 1 (PH1) <b>should be suspected</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with any of the following clinical, radiographic, and/or laboratory features.</p><p><b>Clinical and radiographic features</b></p><ul><li class="half_rhythm"><div>Recurrent nephrolithiasis. Renal ultrasound examination often reveals multiple bilateral radiopaque calculi (computed tomography and kidney ureter bladder x-ray may demonstrate similar findings).</div></li><li class="half_rhythm"><div>Nephrocalcinosis. In older children or adults, the strongest echoes are from the corticomedullary regions, whereas in infants the pattern is more likely to be that of diffuse nephrocalcinosis with few if any observable discrete stones.</div></li><li class="half_rhythm"><div>A child with a first kidney stone [<a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>]</div></li><li class="half_rhythm"><div>A child younger than age 12 months with failure to thrive [<a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>] and impaired kidney function</div></li><li class="half_rhythm"><div>Reduced kidney function or end-stage renal disease at any age with a history of renal stones or nephrocalcinosis [<a class="bk_pop" href="#ph1.REF.edvardsson.2013.1923">Edvardsson et al 2013</a>]</div></li><li class="half_rhythm"><div>Stone composition of pure calcium oxalate monohydrate (whewellite)</div></li><li class="half_rhythm"><div>Oxalate crystals identified in any biologic fluid or tissue [<a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>]</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div><b>Elevated urinary oxalate</b> excretion persistently &#x0003e;0.7 mmol/1.73 m<sup>2</sup>/day or above the age-related reference range(s) (see <a class="figpopup" href="/books/NBK1283/table/ph1.T.normal_values_for_urinary_oxalate/?report=objectonly" target="object" rid-figpopup="figph1Tnormalvaluesforurinaryoxalate" rid-ob="figobph1Tnormalvaluesforurinaryoxalate">Table 1</a>)</div></li><li class="half_rhythm"><div><b>Elevated urinary glycolic acid (glycolate)</b> concentration; occurs in approximately 75% of individuals with PH1 (see <a class="figpopup" href="/books/NBK1283/table/ph1.T.normal_values_for_urinary_oxalate/?report=objectonly" target="object" rid-figpopup="figph1Tnormalvaluesforurinaryoxalate" rid-ob="figobph1Tnormalvaluesforurinaryoxalate">Table 1</a>).</div></li><li class="half_rhythm"><div><b>Elevated plasma oxalate</b> concentration. Individuals with PH1 and well-preserved GFR typically have mildly elevated values. Substantially elevated values are the rule when GFR is &#x0003c;30 mL/min/1.73 m<sup>2</sup> (CKD stages 4 and 5). Plasma oxalate concentrations &#x0003e;50 &#x000b5;mol/L are very suggestive of PH1 [<a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>, <a class="bk_pop" href="#ph1.REF.perinpam.2017.1014">Perinpam et al 2017</a>].</div></li></ul><div id="ph1.T.normal_values_for_urinary_oxalate" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Normal Values for Urinary Oxalate, Glycolate, and L-Glycerate Excretion in 24-Hour Urine and Spot (Random) Urine Samples</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1283/table/ph1.T.normal_values_for_urinary_oxalate/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph1.T.normal_values_for_urinary_oxalate_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parameter</th><th id="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age</th><th id="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Normal Values&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Urinary oxalate excretion&#x000a0;<sup>2</sup></b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">All ages</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><b>In 24-hour</b><br /><b>urine</b><br /><b>samples</b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;0.50 mmol (&#x0003c;45 mg)/1.73 m<sup>2</sup>/day</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Urinary glycolate excretion</b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;0.50 mmol (&#x0003c;45 mg)/1.73 m<sup>2</sup>/day</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Urinary L-glycerate</b><br /><b>concentration</b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;5 &#x003bc;mol/L</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Spot urinary oxalate-to-</b><br /><b>creatinine molar ratio&#x000a0;<sup>3</sup></b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-6 mos&#x000a0;<sup>4</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" rowspan="15" colspan="1" style="text-align:left;vertical-align:middle;"><b>In spot</b><br /><b>urine</b><br /><b>samples</b>&#x000a0;<sup>2</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;325-360 mmol/mol (&#x0003c;253-282 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">7-24 mos&#x000a0;<sup>4</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;132-174 mmol/mol (&#x0003c;103-136 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">2-5 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;98-101 mmol/mol (&#x0003c;76-79 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">5-14 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;70-82 mmol/mol (&#x0003c;55-64 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;16 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;40 mmol/mol (&#x0003c;32 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Spot urinary glycolate-to</b><br /><b>creatinine molar ratio</b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-6 mos&#x000a0;<sup>4</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;363-425 mmol/mol (&#x0003c;241-282 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">7-24 mos&#x000a0;<sup>4</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;245-293 mmol/mol (&#x0003c;163-194 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">2-5 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;191-229 mmol/mol (&#x0003c;127-152 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">5-14 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;166-186 mmol/mol (&#x0003c;110-123 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;16 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;99-125 mmol/mol (&#x0003c;66-83 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Spot urinary L-glycerate-to</b><br /><b>creatinine molar ratio</b></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-6 mos&#x000a0;<sup>4</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">14-205 mmol/mol (&#x0003c;13-192 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">7-24 mos&#x000a0;<sup>4</sup></td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">14-205 mmol/mol (&#x0003c;13-192 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">2-5 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">14-205 mmol/mol (&#x0003c;13-192 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">5-14 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">23-138 mmol/mol (&#x0003c;22-129 mg/g)</td></tr><tr><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;16 yrs</td><td headers="hd_h_ph1.T.normal_values_for_urinary_oxalate_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;138 mmol/mol (&#x0003c;129 mg/g)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#ph1.REF.hoppe.2012.467">Hoppe [2012]</a></p></div></dd><dt>1. </dt><dd><div id="ph1.TF.1.1"><p class="no_margin">Values are laboratory and method dependent.</p></div></dd><dt>2. </dt><dd><div id="ph1.TF.1.2"><p class="no_margin">Urinary excretion of creatinine on a per-kg basis differs between males and females and does not stabilize until ages 14 to 18 years [<a class="bk_pop" href="#ph1.REF.remer.2002.561">Remer et al 2002</a>].</p></div></dd><dt>3. </dt><dd><div id="ph1.TF.1.3"><p class="no_margin">To prevent alkaline conversion of ascorbate to oxalate in urine, the sample must be strongly acidified to stabilize ascorbate and minimize formation of calcium crystals [<a class="bk_pop" href="#ph1.REF.marangella.1995">Marangella &#x00026; Petrarulo 1995</a>].</p></div></dd><dt>4. </dt><dd><div id="ph1.TF.1.4"><p class="no_margin">In children younger than age 1.5-2.0 years, interpretation of random urine oxalate/creatinine ratios is challenging due to rapid age-related changes associated with normal maturation. Normal newborns and young infants/children can excrete &#x02265;3-5x the amount of oxalate excreted by adults; this amount slowly decreases into the normal adult range in the older child [<a class="bk_pop" href="#ph1.REF.leumann.1990.493">Leumann et al 1990</a>, <a class="bk_pop" href="#ph1.REF.von_schnakenburg.1994.27">von Schnakenburg et al 1994</a>, <a class="bk_pop" href="#ph1.REF.marangella.1995">Marangella &#x00026; Petrarulo 1995</a>].</p></div></dd></dl></div></div></div></div><div id="ph1.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>A guideline for diagnosis has been developed [<a class="bk_pop" href="#ph1.REF.edvardsson.2013.1923">Edvardsson et al 2013</a>]; see <a class="figpopup" href="/books/NBK1283/figure/ph1.F1/?report=objectonly" target="object" rid-figpopup="figph1F1" rid-ob="figobph1F1">Figure 1</a> for algorithm. The algorithm also assists the clinician in differentiating between PH types 1, 2, and 3.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figph1F1" co-legend-rid="figlgndph1F1"><a href="/books/NBK1283/figure/ph1.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figph1F1" rid-ob="figobph1F1"><img class="small-thumb" src="/books/NBK1283/bin/ph1-Image001.gif" src-large="/books/NBK1283/bin/ph1-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndph1F1"><h4 id="ph1.F1"><a href="/books/NBK1283/figure/ph1.F1/?report=objectonly" target="object" rid-ob="figobph1F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Algorithm for diagnostic evaluation of primary hyperoxaluria From Edvardsson et al [2013]. Published with permission of SpringerNature.</p></div></div><p>The diagnosis of PH1 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with hyperoxaluria or hyperoxalemia by ONE of the following:</p><ul><li class="half_rhythm"><div>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>AGXT</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1283/table/ph1.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figph1Tmoleculargenetictestingusedin" rid-ob="figobph1Tmoleculargenetictestingusedin">Table 2</a>)<i>.</i> Molecular genetic testing is indicated in all individuals as <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> information helps predict treatment responses (see <a href="#ph1.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</div></li><li class="half_rhythm"><div>Identification of AGT enzyme deficiency on liver biopsy (see <b>Liver biopsy</b>)</div></li></ul><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>AGXT</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Sequence analysis includes testing for the common <i>AGXT</i> polymorphic variant, <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Pro11Leu</a>. Although p.Pro11Leu, referred to as the "minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>," does not cause PH1 by itself, it is known to exacerbate the deleterious effects of other pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration (see <a href="#ph1.Molecular_Pathogenesis">Molecular Genetics</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>AGXT</i> and other genes of interest (e.g., <i>GRHPR</i>, <i>HOGA1</i> [see <a href="#ph1.Differential_Diagnosis">Differential Diagnosis</a>]) is now recommended. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <b><a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a></b> and <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="ph1.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Primary Hyperoxaluria Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1283/table/ph1.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph1.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>AGXT</i></td><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;97%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;3%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_ph1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ph1.TF.2.1"><p class="no_margin">See <a href="/books/NBK1283/#ph1.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ph1.TF.2.2"><p class="no_margin">See <a href="#ph1.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ph1.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ph1.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#ph1.REF.coultermackie.2008.598">Coulter-Mackie et al [2008]</a></p></div></dd><dt>5. </dt><dd><div id="ph1.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ph1.TF.2.6"><p class="no_margin">Out of more than 170 known <i>AGXT</i> pathogenic variants, six large deletions have been reported [<a class="bk_pop" href="#ph1.REF.nogueira.2000.384">Nogueira et al 2000</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2001.314">Coulter-Mackie et al 2001</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2005.172">Coulter-Mackie et al 2005</a>, <a class="bk_pop" href="#ph1.REF.monico.2007.1905">Monico et al 2007</a>, <a class="bk_pop" href="#ph1.REF.williams.2009.910">Williams et al 2009</a>, <a class="bk_pop" href="#ph1.REF.tammachote.2012.2124">Tammachote et al 2012</a>].</p></div></dd><dt>7. </dt><dd><div id="ph1.TF.2.7"><p class="no_margin">The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in PH2 and PH3 can appear similar to PH1 (without detailed biochemical analysis), 11.3% of families with a PH-like phenotype were not found to have pathogenic variants in <i>AGXT</i>, <i>GRHPR</i>, or <i>HOGA1</i> [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. It is not known what percentage of these individuals have PH1.</p></div></dd></dl></div></div></div><p><b>Liver biopsy.</b> If urinary glycerate, 4-hydroxyoxoglutarate (HOG), and dihydroxyglutarate <b>(</b>DHG) are normal, and no <i>AGXT</i>, <i>GRHPR</i>, or <i>HOGA1</i> pathogenic variants are identified, liver biopsy can be performed to assay alanine:glyoxylate-aminotransferase (AGT), glyoxylate reductase (GR), and 4-hydroxy-2-oxoglutarate aldolase (HOGA) enzyme activity. Normal GR and HOGA enzyme activity will rule out PH types 2 and 3 as the cause of the hyperoxaluria (see <a href="/books/n/gene/ph2/">Primary Hyperoxaluria Type 2</a> and <a href="/books/n/gene/ph3/">Primary Hyperoxaluria Type 3</a>). Individuals with clinical features suggestive of PH who have AGT enzyme deficiency on liver biopsy and do not have identified <i>AGXT</i> pathogenic variants have a presumed diagnosis of PH1. Individuals who do not have identifed pathogenic variants in <i>AGXT</i>, <i>GRHPR</i>, or <i>HOGA1</i> accounted for 11.3% of individuals with hyperoxaluria tested in one recent series [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>].</p></div></div><div id="ph1.Clinical_Characteristics"><h2 id="_ph1_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ph1.Clinical_Description"><h3>Clinical Description</h3><p>In primary hyperoxaluria type 1 (PH1), high concentrations of oxalate in the urine combine with calcium resulting in calcium oxalate crystal formation. Crystal deposition leads to nephrolithiasis in the urinary tract, renal tubular damage, and nephrocalcinosis when the crystals deposit in the renal parenchyma. Progressive kidney damage and ultimately renal failure ensue. As declining glomerular filtration rate (GFR) limits excretion of the excess oxalate, plasma levels rise rapidly. Supersaturation of calcium oxalate in plasma then results in calcium oxalate deposition in many organs and tissues (oxalosis) with systemic manifestations.</p><p>The clinical presentation of PH1 is variable. Age at onset of symptoms ranges from early infancy to the sixth decade (median age: 4-6 years) [<a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>, <a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. The majority of individuals present with symptoms related to nephrolithiasis. Some present with a severe, very early-onset form of PH1 in the first year of life characterized by failure to thrive and end-stage renal disease (ESRD). At the other end of the spectrum of clinical severity seen in PH1, some individuals remain free of symptoms or minimally symptomatic into the sixth decade of life [<a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p><b>Renal manifestations.</b> The renal manifestations of PH1 can be quite variable, with individuals generally falling into one of five groups:</p><ul><li class="half_rhythm"><div>Early nephrocalcinosis and renal failure in infancy or early childhood (accounts for ~10% of individuals with PH1 in Europe and North America)</div></li><li class="half_rhythm"><div>Recurrent nephrolithiasis and progressive renal failure with diagnosis in childhood, adolescence, or early to mid-adulthood (accounts for majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals)</div></li><li class="half_rhythm"><div>Diagnosis after ESRD that is first recognized due to oxalate deposits on renal biopsy, recurrent oxalate nephropathy in a renal allograft following renal transplantation or due to systemic oxalosis developing during chronic dialysis. (~10% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals)</div></li><li class="half_rhythm"><div>Late-onset form with occasional stones diagnosed in adulthood (&#x0003c;10%)</div></li><li class="half_rhythm"><div>Diagnosis in a presymptomatic individual because of a positive family history (&#x0003c;10%)</div></li></ul><p>In individuals with severe, early-onset (infantile) disease, the presenting signs and symptoms include nephrocalcinosis with or without nephrolithiasis and failure to thrive related to renal failure. ESRD can appear as early as age four to six months. In most series in Europe and the US severe infantile oxalosis with kidney failure accounts for 10% or less of individuals with PH1 [<a class="bk_pop" href="#ph1.REF.harambat.2010.443">Harambat et al 2010</a>, <a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. However, the proportion appears higher in some areas of the world [<a class="bk_pop" href="#ph1.REF.cochat.2006.1075">Cochat et al 2006</a>]. One limitation of current understanding of the natural history of PH1 is that a large majority of individuals and nearly all large reported series are from Europe and North America.</p><p>Presenting symptoms from early childhood through adolescence are most often related to kidney stone disease including hematuria, dysuria, pain, urinary tract infection, or stone passage [<a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>]. Nephrocalcinosis is common [<a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>]. Initial symptoms occur in most individuals before age ten years, and in 85%-90% by age 20 years [<a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>, <a class="bk_pop" href="#ph1.REF.van_der_hoeven.2012.3855">van der Hoeven et al 2012</a>, <a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>]. Median age of onset of symptoms was 3.9 to 5.2 years [<a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>The remainder of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals present in <b>adulthood</b> with recurrent renal stones [<a class="bk_pop" href="#ph1.REF.van_der_hoeven.2012.3855">van der Hoeven et al 2012</a>]. Many adults report a history of unrecognized symptoms and missed or delayed diagnosis. A mild-to-moderate reduction in kidney function is common, though the rate of decline is highly variable. Some individuals, mainly adults, may present with acute renal failure secondary to bilateral renal obstruction caused by calcium oxalate stones or due to other illnesses that compromise fluid intake and thus urine volume. Acute renal failure has also been reported following stone removal procedures [<a class="bk_pop" href="#ph1.REF.carrasco.2015.522">Carrasco et al 2015</a>]. Twenty percent to 50% of individuals with adult-onset PH1 were diagnosed when they presented in the late stages of chronic kidney disease (CKD) or ESRD [<a class="bk_pop" href="#ph1.REF.harambat.2012.458">Harambat et al 2012</a>, <a class="bk_pop" href="#ph1.REF.van_der_hoeven.2012.3855">van der Hoeven et al 2012</a>, <a class="bk_pop" href="#ph1.REF.zhao.2016.119">Zhao et al 2016</a>]. A higher prevalence of ESRD without a prior history of renal stones was observed in a national study of individuals with PH1 from the Netherlands [<a class="bk_pop" href="#ph1.REF.van_woerden.2003.273">van Woerden et al 2003</a>]. The proportion of individuals with ESRD at the time of diagnosis is higher in adults than in children [<a class="bk_pop" href="#ph1.REF.van_der_hoeven.2012.3855">van der Hoeven et al 2012</a>, <a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>]. The median age of individuals with PH1 who reach ESRD prior to diagnosis is 25 years (range: early childhood to late middle age) [<a class="bk_pop" href="#ph1.REF.zhao.2016.119">Zhao et al 2016</a>]. In approximately 10% of individuals the diagnosis of PH1 is made only following recurrence in a renal transplant when calcium oxalate crystals are found on allograft biopsy performed for early nonfunction of the transplanted kidney or a subsequent increase in serum creatinine [<a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>].</p><p><b>Progression to renal failure</b> has been shown to correlate with urine oxalate excretion rate and with nephrocalcinosis [<a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>, <a class="bk_pop" href="#ph1.REF.zhao.2016.119">Zhao et al 2016</a>]. <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a> is associated with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, with lower urine oxalate excretion, responsiveness to pyridoxine treatment, and later onset of ESRD [<a class="bk_pop" href="#ph1.REF.monico.2005a.183">Monico et al 2005a</a>, <a class="bk_pop" href="#ph1.REF.harambat.2010.443">Harambat et al 2010</a>, <a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. Later onset of ESRD has also been reported with the mistargeting pathogenic variant p.Phe152Ile [<a class="bk_pop" href="#ph1.REF.mandrile.2014.1197">Mandrile et al 2014</a>]; other mistargeting pathogenic variants do not appear to delay the onset of ESRD [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. The natural history of untreated PH1 is one of progressive decline in renal function as a result of calcium oxalate deposits in kidney tissue and complications of nephrolithiasis such as obstruction and infection. A recent study found renal survival in individuals with PH1 to be 76%, 43%, and 12% at ages 20, 40, and 60 years, respectively [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. Another study noted renal survival of 59%, 41%, and 10% at ages 20, 30, and 50 years, respectively [<a class="bk_pop" href="#ph1.REF.harambat.2010.443">Harambat et al 2010</a>]. In the absence of treatment there is eventual progression to oxalosis and death from ESRD and/or complications of oxalosis [<a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>, <a class="bk_pop" href="#ph1.REF.harambat.2010.443">Harambat et al 2010</a>, <a class="bk_pop" href="#ph1.REF.van_der_hoeven.2012.3855">van der Hoeven et al 2012</a>, <a class="bk_pop" href="#ph1.REF.cochat.2013.2273">Cochat &#x00026; Groothoff 2013</a>].</p><p>Among 54 children and adolescents with PH1 who developed ESRD from 2000 through 2009, five-year survival was 83% following initiation of renal replacement therapy. Results showed improvement compared with renal replacement therapy prior to 2000, particularly in children younger than age two years. However, outcomes were less favorable in children with PH1 who required renal replacement compared to children with other renal diseases [<a class="bk_pop" href="#ph1.REF.harambat.2012.458">Harambat et al 2012</a>]. In a series of six individuals with PH1 with infantile oxalosis, excellent outcomes were reported following combined kidney/liver transplantation at a mean age of 14.8 months following a mean of 11.8 months of dialysis [<a class="bk_pop" href="#ph1.REF.millan.2003.1458">Millan et al 2003</a>].</p><p><b>Oxalosis.</b> When the GFR is &#x0003c;30 mL/min/1.73 m<sup>2</sup>, the daily production of oxalate outstrips renal oxalate clearance, resulting in acceleration of the rise in plasma oxalate concentration associated with declining GFR, and further loss in residual renal function. Supersaturation in plasma leads to deposition of calcium oxalate crystals in multiple body tissues (oxalosis), including the kidneys, retina, myocardium, blood vessels, bone, bone marrow, and subcutaneous tissue [<a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>, <a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>, <a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>]. Peripheral nerves, synovia, and other tissues may also be involved [<a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>]. Clinical manifestations may include visual disturbance, cardiac conduction disturbances such as heart block, and cardiomyopathy. Vascular involvement can lead to ischemia, most often manifest as non-healing cutaneous ulcers. Though unusual, cerebral infarcts have been reported from calcium oxalate in cerebral vessels [<a class="bk_pop" href="#ph1.REF.rao.2014.411">Rao et al 2014</a>]. Refractory hypotension can be seen in advanced oxalosis. Bone is the largest repository for excess oxalate. Oxalate osteodystrophy causes bone pain and pathologic fractures. Involvement of bone marrow can result in anemia refractory to erythropoietin-stimulating agents (ESA). Dental pain due to oxalate deposition and root resorption have been described [<a class="bk_pop" href="#ph1.REF.mitsimponas.2012.e301">Mitsimponas et al 2012</a>]. Peripheral neuropathy can be caused by crystal deposition within nerve [<a class="bk_pop" href="#ph1.REF.berini.2015.449">Berini et al 2015</a>]. Progressive oxalosis, observed over time in most individuals with PH on dialysis, eventually leads to death. Oxalosis is slowly reversible following successful liver and kidney transplantation, but mobilization of the tissue deposits poses risk for a transplanted kidney.</p><p>Bone mineral density measurements, as opposed to the gold standard of bone biopsy, allow for noninvasive assessment of oxalate burden [<a class="bk_pop" href="#ph1.REF.behnke.2001.2236">Behnke et al 2001</a>], though interpretation of bone density is complicated by multiple bone changes related to ESRD.</p></div><div id="ph1.Pathophysiology"><h3>Pathophysiology</h3><p>The stone type most prevalent in individuals with PH1 is calcium oxalate monohydrate or whewellite [<a class="bk_pop" href="#ph1.REF.daudon.2008.100">Daudon et al 2008</a>]. These authors noted that stones from individuals with PH1 differ in morphologic characteristics from <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> calcium oxalate stone formers: they appear white or pale yellow on the surface and form a loose, unorganized section whereas idiopathic oxalate stone formers appear as a dark-brown surface with a well-organized radiating inner structure. These differences in morphology suggest a different mechanism of stone formation from idiopathic oxalate stones.</p></div><div id="ph1.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Pathogenic variants that result in mistargeting of alanine:glyoxylate-aminotransferase (AGT) enzyme activity (see <a href="#ph1.Molecular_Genetics">Molecular Genetics</a>, <b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>) are the most likely to be associated with B<sub>6</sub> (pyridoxine) responsiveness [<a class="bk_pop" href="#ph1.REF.monico.2005a.183">Monico et al 2005a</a>].</p><ul><li class="half_rhythm"><div>Homozygotes for either c.508G&#x0003e;A (<a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a>) or c.454T&#x0003e;A (<a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Phe152Ile</a>) show B<sub>6</sub> responsiveness and benefit from early treatment (see <a href="#ph1.Management">Management</a>).</div></li><li class="half_rhythm"><div>Response to B<sub>6</sub> therapy is relative to the number of copies of the p.Gly170Arg <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> present [<a class="bk_pop" href="#ph1.REF.monico.2005a.183">Monico et al 2005a</a>, <a class="bk_pop" href="#ph1.REF.monico.2005b.1704">Monico et al 2005b</a>]. Compound heterozygotes for these pathogenic variants also demonstrate a reduction in urine oxalate following B<sub>6</sub> treatment, though less than observed in homozygotes.</div></li><li class="half_rhythm"><div>Results of in vitro studies suggest that additional pathogenic variants may respond to B<sub>6</sub>, reinforcing the recommendation of testing all individuals for B<sub>6</sub> responsiveness [<a class="bk_pop" href="#ph1.REF.fargue.2013b.1776">Fargue et al 2013b</a>].</div></li></ul><p>The presence of the <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is associated with lower urine oxalate excretion rates even in the absence of treatment and could even predict disease severity and/or rate of progression [<a class="bk_pop" href="#ph1.REF.monico.2005a.183">Monico et al 2005a</a>, <a class="bk_pop" href="#ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al 2014</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. A large retrospective study of individuals with PH1 suggested that the p.Gly170Arg pathogenic variant is associated with longer preservation of renal function with conservative treatment compared to other pathogenic variants [<a class="bk_pop" href="#ph1.REF.harambat.2010.443">Harambat et al 2010</a>].</p><p>Although it may be possible to establish a relationship between the <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and AGT enzyme activity in vitro, in most cases it is difficult to correlate enzyme activity with clinical severity [<a class="bk_pop" href="#ph1.REF.danpure.2001">Danpure 2001</a>, <a class="bk_pop" href="#ph1.REF.pirulli.2003.297">Pirulli et al 2003</a>, <a class="bk_pop" href="#ph1.REF.danpure.2004.1">Danpure &#x00026; Rumsby 2004</a>, <a class="bk_pop" href="#ph1.REF.van_woerden.2004.746">van Woerden et al 2004</a>].</p><p>The clinical course of PH1 in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs is usually similar; however, families in which affected relatives with identical pathogenic variants had different disease manifestations have been described [<a class="bk_pop" href="#ph1.REF.frishberg.2005.269">Frishberg et al 2005</a>, <a class="bk_pop" href="#ph1.REF.beck.2006.984">Beck &#x00026; Hoppe 2006</a>, <a class="bk_pop" href="#ph1.REF.lorenzo.2006.1115">Lorenzo et al 2006</a>, <a class="bk_pop" href="#ph1.REF.mandrile.2008.309">Mandrile et al 2008</a>, <a class="bk_pop" href="#ph1.REF.alfadhel.2012.373">Alfadhel et al 2012</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. Possible causes of this intrafamilial variation include differences in activity level of other enzymes important in oxalate synthesis, modifier genes, the quantity of oxalate precursors in the diet, renal oxalate handling, absorption of dietary oxalate, hydration status, infections, and urinary crystallization factors [<a class="bk_pop" href="#ph1.REF.danpure.2001">Danpure 2001</a>].</p><p>Other than potential delay in diagnosis due to the rarity of PH1, the reason for a poorer outcome in infants with the same pathogenic variants as older individuals is not clear. Possibilities include:</p><ul><li class="half_rhythm"><div>The low glomerular filtration rate (both absolute and corrected) in children younger than age six to 12 months, which predisposes to earlier oxalate deposition [<a class="bk_pop" href="#ph1.REF.quigley.2012.184">Quigley 2012</a>];</div></li><li class="half_rhythm"><div>High oxalate excretion in infants (<a class="figpopup" href="/books/NBK1283/table/ph1.T.normal_values_for_urinary_oxalate/?report=objectonly" target="object" rid-figpopup="figph1Tnormalvaluesforurinaryoxalate" rid-ob="figobph1Tnormalvaluesforurinaryoxalate">Table 1</a>);</div></li><li class="half_rhythm"><div>Reduced number of nephrons present at birth, which may be associated with low birth weight as well as environmental and genetic factors [<a class="bk_pop" href="#ph1.REF.luyckx.2005.s68">Luyckx &#x00026; Brenner 2005</a>, <a class="bk_pop" href="#ph1.REF.puddu.2009.162">Puddu et al 2009</a>, <a class="bk_pop" href="#ph1.REF.luyckx.2010.898">Luyckx &#x00026; Brenner 2010</a>].</div></li></ul></div><div id="ph1.Nomenclature"><h3>Nomenclature</h3><p>With the identification of oxalate in human urine in the 1800s, hyperoxaluria fell into a category referred to as "oxalate diathesis" &#x02013; a catch-all term for a wide variety of ailments.</p><p>PH1 can be considered a peroxisomal disorder, as it results from deficiency of a single peroxisomal enzyme. PH1, however, is distinct from disorders of peroxisomal biogenesis (see <a href="/books/n/gene/pbd/">Peroxisomal Biogenesis Disorders, Zellweger Type</a> and <a href="/books/n/gene/rcdp/">Rhizomelic Chondrodysplasia Punctata Type 1</a>) in that a normal number of relatively normal-looking peroxisomes are observed on liver biopsy.</p></div><div id="ph1.Prevalence"><h3>Prevalence</h3><p>PH1 is estimated to account for 1%-2% of children with end-stage renal disease (ESRD) [<a class="bk_pop" href="#ph1.REF.harambat.2012.458">Harambat et al 2012</a>].</p><p>When considering the following statistics, it is important to remember that PH1 remains underdiagnosed because of the wide variability in its clinical presentation and age of onset.</p><p>Clinical estimates of prevalence of PH1, primarily from European studies, range from one to three in 1,000,000 [<a class="bk_pop" href="#ph1.REF.van_woerden.2003.273">van Woerden et al 2003</a>, <a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>]. PH1 is estimated to occur in 1:120,000 live births in Europe [<a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>]. Since phenotypic heterogeneity ranges from severe disease in infancy to adults with recurrent stones, and since advanced disease is present in 20%-50% at the time of diagnosis, underdiagnosis likely occurs. Population analysis based on <i>AGXT</i> pathogenic variants identified in the National Heart, Lung, and Blood Institute Exome Sequencing Project suggest a PH1 prevalence of 1:149,000 in European Americans and 1:157,000 in African Americans [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>A higher frequency of PH1 has been reported in Tunisia and Kuwait [<a class="bk_pop" href="#ph1.REF.kamoun.1996.479">Kamoun &#x00026; Lakhoua 1996</a>, <a class="bk_pop" href="#ph1.REF.aleisa.2004.1788">Al-Eisa et al 2004</a>, <a class="bk_pop" href="#ph1.REF.cochat.2006.1075">Cochat et al 2006</a>], in Arabs and Druze families of Israel [<a class="bk_pop" href="#ph1.REF.rinat.1999.2352">Rinat et al 1999</a>], and in Iran [<a class="bk_pop" href="#ph1.REF.madani.2001.140">Madani et al 2001</a>] as a result of the high rate of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> in these populations. No common <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> has been identified in these populations [<a class="bk_pop" href="#ph1.REF.rinat.1999.2352">Rinat et al 1999</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2005.264">Coulter-Mackie 2005</a>, <a class="bk_pop" href="#ph1.REF.frishberg.2005.269">Frishberg et al 2005</a>].</p></div></div><div id="ph1.Genetically_Related_Allelic_Disorder"><h2 id="_ph1_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>AGXT</i>.</p></div><div id="ph1.Differential_Diagnosis"><h2 id="_ph1_Differential_Diagnosis_">Differential Diagnosis</h2><p><a href="/books/n/gene/ph2/"><b>Primary hyperoxaluria type 2</b></a>
<b>(PH2)</b> is caused by pathogenic variants in <i>GRHPR,</i> resulting in deficiency of the cytosolic enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR), which catalyzes the reduction of glyoxylate and hydroxypyruvate to D-glycerate. While found in many tissues, GRHPR is mainly found in hepatocytes with some expression in mitochondria. In PH2, glyoxylate removal is impaired, resulting in the metabolism of glyoxylate by lactate dehydrogenase to oxalate and L-glycerate.</p><p>The diagnosis of PH2 can be established by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>GHPRH</i> or assay of GRHPR enzymatic activity in liver. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p>PH2 is rarer than PH1. It is associated with better preservation of kidney function than PH1 [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>From a small cohort of individuals with PH1 and PH2 from one center, PH1 as a group appears to differ from PH2 in the following respects:</p><ul><li class="half_rhythm"><div>PH2 is considered a less aggressive disease than PH1, even when onset is early.</div></li><li class="half_rhythm"><div>Individuals with PH1 have statistically higher urine oxalate excretions and more stone-forming activity and thus require more frequent stone removal.</div></li><li class="half_rhythm"><div>Individuals with PH1 have statistically lower urine osmolalities and lower urine concentration of calcium, citrate, and magnesium. (For a single individual with hyperoxaluria, the differences observed <b>cannot</b> reliably distinguish PH1 from PH2.)</div></li><li class="half_rhythm"><div>In individuals with PH1, urinary glycolate (as well as oxalate) is often elevated, although some individuals with PH1 have normal urine glycolate.</div></li><li class="half_rhythm"><div>In individuals with PH2, urinary L-glycerate and oxalate are generally elevated; a single individual with PH2 and normal urine glycerate has been reported [<a class="bk_pop" href="#ph1.REF.rumsby.2001.1697">Rumsby et al 2001</a>].</div></li></ul><p><a href="/books/n/gene/ph3/"><b>Primary hyperoxaluria type 3</b></a>
<b>(PH3)</b> is caused by a defect in the hepatocyte-specific mitochondrial enzyme 4-hydroxy-2-oxoglutarate aldolase (HOGA), which appears to lead to excess metabolism of hydroxyproline with the forward reaction product (HOG) itself being converted to pyruvate or glyoxalate or perhaps actually inhibiting mitochondrial GRHPR (effectively causing "secondary" PH2). Pathogenic variants in <i>HOGA1</i> are causative. Diagnosis is by exclusion of PH1 and PH2 with confirmation by DNA <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>HOGA1</i>. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><b>Enteric hyperoxaluria.</b> Diseases affecting the small bowel that result in fat malabsorption including <a href="/books/n/gene/celiac/">celiac disease</a>, Crohn's disease, <a href="/books/n/gene/pancreatitis-ov/">pancreatitis</a>, and short bowel syndrome can be associated with hyperoxaluria. The precipitation of enteric calcium by non-absorbed free fatty acids leads to loss of the normal inhibition in oxalate reabsorption from the gut, increasing plasma oxalate concentration by increasing paracellular and transcellular transport. Delivery of excess fatty acids and bile salts to the colon also injures the mucosa and increases oxalate absorption [<a class="bk_pop" href="#ph1.REF.milliner.2005.154">Milliner 2005</a>, <a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>]. By contrast, individuals with PH1 show low-to-normal levels of oxalate absorption [<a class="bk_pop" href="#ph1.REF.sikora.2008.1181">Sikora et al 2008</a>]. Gastric bypass procedures used in the treatment of obesity have been associated with increased oxalate absorption, high levels of hyperoxaluria, increased risk of kidney stone formation, and ESRD caused by oxalate nephropathy [<a class="bk_pop" href="#ph1.REF.asplin.2007.565">Asplin &#x00026; Coe 2007</a>, <a class="bk_pop" href="#ph1.REF.kleinman.2007.8">Kleinman 2007</a>, <a class="bk_pop" href="#ph1.REF.duffey.2008.1145">Duffey et al 2008</a>, <a class="bk_pop" href="#ph1.REF.lieske.2008.163">Lieske et al 2008</a>]. Urinary risk factors for stones such as hyperoxaluria occur more commonly in individuals with Roux-en-Y gastric bypass than gastric banding [<a class="bk_pop" href="#ph1.REF.semins.2010.826">Semins et al 2010</a>, <a class="bk_pop" href="#ph1.REF.kumar.2011.654">Kumar et al 2011</a>, <a class="bk_pop" href="#ph1.REF.tasca.2011.129">Tasca 2011</a>].</p><p><b>Dietary hyperoxaluria.</b> Excess intake of foods high in oxalate including chocolate, cocoa, leafy greens (especially rhubarb and spinach), black tea, nuts, peanut butter, or starfruit [<a class="bk_pop" href="#ph1.REF.holmes.2000.1662">Holmes &#x00026; Kennedy 2000</a>, <a class="bk_pop" href="#ph1.REF.monk.2000">Monk &#x00026; Bushinsky 2000</a>] may lead to elevated plasma concentration of oxalate and hence increased urinary concentration of oxalate. It was previously thought that dietary oxalate accounted for little of the oxalate in the urine (&#x0003c;10%), but <a class="bk_pop" href="#ph1.REF.holmes.2001b.270">Holmes et al [2001b]</a> showed that between 24% and 53% of urinary oxalate is attributable to oxalate from the diet [<a class="bk_pop" href="#ph1.REF.holmes.2004.311">Holmes &#x00026; Assimos 2004</a>]. Therapy consists of dietary oxalate restriction and use of calcium carbonate or calcium citrate at meal times to bind dietary oxalate [<a class="bk_pop" href="#ph1.REF.penniston.2009.484">Penniston &#x00026; Nakada 2009</a>].</p><p><b>Idiopathic calcium oxalate urolithiasis</b> is associated with "mild metabolic hyperoxaluria." Features that often differentiate this condition from PH1:</p><ul><li class="half_rhythm"><div>Lower urinary oxalate excretion</div></li><li class="half_rhythm"><div>Less severe stone disease</div></li><li class="half_rhythm"><div>The hyperoxaluria rarely leads to ESRD.</div></li><li class="half_rhythm"><div>Tendency to hypercalciuria (as opposed to hypocalciuria in PH1)</div></li><li class="half_rhythm"><div>Day-to-day variability in the levels of urinary oxalate excretion (in contrast to PH1, in which levels are persistently elevated in the urine [<a class="bk_pop" href="#ph1.REF.milliner.2005.154">Milliner 2005</a>])</div></li></ul><p><a href="/books/n/gene/dent/"><b>Dent disease</b></a><b>.</b> The clinical features of Dent disease may overlap those of PH1. Both are associated with nephrocalcinosis and urolithiasis in childhood and progress to renal failure (see <a class="figpopup" href="/books/NBK1283/table/ph1.T.clinical_and_diagnostic_features_o/?report=objectonly" target="object" rid-figpopup="figph1Tclinicalanddiagnosticfeatureso" rid-ob="figobph1Tclinicalanddiagnosticfeatureso">Table 3</a>).</p><div id="ph1.T.clinical_and_diagnostic_features_o" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Clinical and Diagnostic Features of Dent Disease and Primary Hyperoxaluria Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1283/table/ph1.T.clinical_and_diagnostic_features_o/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph1.T.clinical_and_diagnostic_features_o_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical and Diagnostic Features</th><th id="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dent Disease</th><th id="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PH1</th></tr></thead><tbody><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nephrocalcinosis</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3+</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2+</td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urolithiasis</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3+</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4+</td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Osteodystrophy</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1+</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1+&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal failure</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2+</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2+</td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypercalciuria</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1+</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02014;</td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperoxaluria</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02014;</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3+</td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low-molecular-weight proteinuria</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1+</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02014;&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CLCN5</i></td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AGXT</i></td></tr><tr><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inheritance</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">X linked</td><td headers="hd_h_ph1.T.clinical_and_diagnostic_features_o_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autosomal recessive</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">From <a class="bk_pop" href="#ph1.REF.milliner.2006.27">Milliner [2006]</a></p></div></dd><dt>1. </dt><dd><div id="ph1.TF.3.1"><p class="no_margin">After renal failure established</p></div></dd><dt>2. </dt><dd><div id="ph1.TF.3.2"><p class="no_margin">May be observed following renal damage but not an early or characteristic finding</p></div></dd></dl></div></div></div><p><b>Other hereditary causes of kidney stones.</b> A number of common and rare forms of nephrocalcinosis or urolithiasis may be associated with kidney disease [<a class="bk_pop" href="#ph1.REF.monico.2011.151">Monico &#x00026; Milliner 2011</a>, <a class="bk_pop" href="#ph1.REF.edvardsson.2013.1923">Edvardsson et al 2013</a>].</p><ul><li class="half_rhythm"><div>Another condition that may present with findings of nephrolcalcinosis is <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) (OMIM <a href="http://omim.org/entry/248250" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">248250</a>).</div></li><li class="half_rhythm"><div>While not associated with nephrocalcinosis, children with adenine phosphoribosyltransferase (APRT) deficiency (OMIM <a href="http://omim.org/entry/614723" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614723</a>) can develop crystal nephropathy and chronic kidney disease, as do children with PH1. Hyperoxaluria is not a feature of APRT deficiency, though 2,8-dihydroxyadenine (DHA) crystals in kidney tissue can resemble those of calcium oxalate.</div></li></ul><p><b>Other.</b> Acute renal failure secondary to oxalate deposition in the kidneys has occurred in persons taking large doses ("megadoses") of ascorbic acid (vitamin C) [<a class="bk_pop" href="#ph1.REF.petrarulo.1998.23">Petrarulo et al 1998</a>, <a class="bk_pop" href="#ph1.REF.mashour.2000.561">Mashour et al 2000</a>] as well as in a number of persons who were "juicing" (extraction of juice from vegetables or fruit) with high oxalate-containing foods [<a class="bk_pop" href="#ph1.REF.getting.2013.768">Getting et al 2013</a>].</p><p>Ingestion of ethylene glycol, an oxalate precursor, can lead to excess production and increased concentrations of oxalate in both the plasma and urine [<a class="bk_pop" href="#ph1.REF.milliner.2005.154">Milliner 2005</a>].</p><p>Hyperoxaluria in association with total parenteral nutrition has been described in premature infants [<a class="bk_pop" href="#ph1.REF.sikora.2003.2194">Sikora et al 2003</a>] and adults [<a class="bk_pop" href="#ph1.REF.buchman.1995.24">Buchman et al 1995</a>].</p><p>Hyperoxaluria has been documented in <a href="/books/n/gene/pbd/">peroxisomal biogenesis disorders, Zellweger spectrum</a> despite the apparent cytoplasmic stability of alanine:glyoxylate aminotransferase [<a class="bk_pop" href="#ph1.REF.van_woerden.2006.346">van Woerden et al 2006</a>]. The presence of hyperoxaluria was statistically correlated with the degree of neurologic involvement.</p></div><div id="ph1.Management"><h2 id="_ph1_Management_">Management</h2><div id="ph1.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>The following evaluations are recommended in part based on the guidelines and suggestions of the European hyperoxaluria consortium (<a href="http://www.oxaleurope.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OxalEurope</a>) [<a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>] (see <a class="figpopup" href="/books/NBK1283/table/ph1.T.clinical_and_diagnostic_features_o/?report=objectonly" target="object" rid-figpopup="figph1Tclinicalanddiagnosticfeatureso" rid-ob="figobph1Tclinicalanddiagnosticfeatureso">Table 3</a>), and <a class="bk_pop" href="#ph1.REF.hoppe.2012.467">Hoppe [2012]</a>.</p><ul><li class="half_rhythm"><div>For those with preserved renal function (i.e., GFR &#x0003e;60 mL/min/1.73 m<sup>2</sup>):</div><ul><li class="half_rhythm"><div>Renal ultrasound examination and fundoscopic eye examination to identify the presence/extent of oxalate deposition</div></li><li class="half_rhythm"><div>Baseline urinalysis and measurement of oxalate and creatinine, preferably in a 24-hour collection</div></li></ul></li><li class="half_rhythm"><div>For those with a GFR &#x0003c;60 mL/min/1.73 m<sup>2</sup>, in addition to the above evaluations: measurement of plasma oxalate</div></li><li class="half_rhythm"><div>For those with a GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup> or in whom there is a rapid deterioration in function, in addition to the above evaluations:</div><ul><li class="half_rhythm"><div>Bone x-rays to evaluate for radiodense metaphyseal bands and diffuse demineralization or evidence of pathologic fractures</div></li><li class="half_rhythm"><div>Hemoglobin to evaluate for anemia associated with either renal dysfunction or marrow deposition of oxalate. Bone marrow examination may be needed.</div></li><li class="half_rhythm"><div>Electrocardiogram to evaluate for an associated atrioventricular block</div></li><li class="half_rhythm"><div>Echocardiogram for evidence of oxalate cardiomyopathy which may show changes in refractile characteristics of myocardium and/or reduced ejection fraction</div></li><li class="half_rhythm"><div>Ultrasound and/or CT scan of the heart and viscera for calcifications</div></li><li class="half_rhythm"><div>History and physical examination to assess the risk of arterial insufficiency or ischemia based on vessel wall deposition</div></li><li class="half_rhythm"><div>Thyroid function testing</div></li></ul></li></ul><p>Consultation with a clinical geneticist and/or genetic counselor is recommended.</p></div><div id="ph1.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="ph1.Reduction_of_Urinary_Calcium_Oxalate"><h4>Reduction of Urinary Calcium Oxalate Supersaturation</h4><p>The general therapies for nephrolithiasis benefit all individuals with PH1. Early diagnosis and initiation of conservative therapy are critical in preserving adequate renal function for as long as possible [<a class="bk_pop" href="#ph1.REF.fargue.2009.767">Fargue et al 2009</a>].</p><ul><li class="half_rhythm"><div>Drinking large volumes of fluid (2-3 L/m<sup>2</sup>/24 hours) at regular intervals over the entire day/night prevents calcium oxalate supersaturation. Small children may require a gastrostomy or nasogastric tube for feeds and fluid supplementation. Extreme care should be taken during any illness that could lead to hypovolemia or decreased oral fluid intake; individuals should be advised to seek early medical attention with initiation of intravenous fluids if needed to maintain urine volume.</div></li><li class="half_rhythm"><div>Alkalinzation of urine (pH 6.2-6.8) to inhibit calcium oxalate crystallization using oral potassium citrate at a dose of 0.1-0.15 mg/kg or 0.3-0.5 mmol/kg/day in 3-4 divided doses so long as the GFR is preserved. When the GFR is reduced or concerns about potassium levels ensue, alkalinization can be achieved with sodium citrate.</div></li><li class="half_rhythm"><div>Moderate doses of pyrophosphate-containing solutions may also inhibit crystal formation, and may be dosed as 20-30 mg/kg/day of phosphate in divided doses.</div></li><li class="half_rhythm"><div>Since the excess oxalate in PH1 is derived from endogenous metabolism and is not related to dietary oxalate intake, dietary restriction of oxalate is of little benefit. The principle of careful food choices (avoid high oxalate food and drink) is appropriate without strict limits.</div></li><li class="half_rhythm"><div>Some have advocated use of thiazide medications in PH1. However, urinary calcium is usually in the low normal range or below in individuals with PH1. There is also potential for intravascular volume depletion with thiazide medication. The benefits of thiazide diuretics have not been systematically studied in PH. For these reasons, the authors suggest that they be used on an individual basis only, when specific clinical circumstances warrant.</div></li></ul></div><div id="ph1.Treatment_of_Kidney_Stones"><h4>Treatment of Kidney Stones</h4><p>Individuals with PH1 must be counseled regarding the different success rates of the following surgical modalities:</p><ul><li class="half_rhythm"><div>Shockwave lithotripsy (SWL) is a viable first option, but has a lower success rate and higher rate of subsequent endoscopic surgery. Calcium oxalate monohydrate stones are among the hardest stones, and are thus more likely to be resistant to SWL [<a class="bk_pop" href="#ph1.REF.williams.2003.1092">Williams et al 2003</a>]. Stones in the lower pole of the kidney or parenchymal stones did not respond as well to SWL as stones in other locations [<a class="bk_pop" href="#ph1.REF.alabadi.2013.1085">Al-Abadi &#x00026; Hulton 2013</a>]. There is good evidence that any given stone should not be treated with more than two SWL sessions, particularly if no change is observed with treatment [<a class="bk_pop" href="#ph1.REF.pace.2000.1905">Pace et al 2000</a>].</div></li><li class="half_rhythm"><div>Ureteroscopy holds a very good record for success of stone clearance with minimal complication rates and may be supplanting SWL as first-line therapy at many centers.</div></li></ul><p>&#x02022; Percutaneous nephrolithotomy should be considered as first-line therapy for larger, bulky stone burdens (&#x0003e;15 mm).</p></div><div id="ph1.Reduction_of_Oxalate_Biosynthesis"><h4>Reduction of Oxalate Biosynthesis</h4><p>Alanine:glyoxylate aminotransferase (AGT) is a pyridoxal phosphate (PLP)-dependent enzyme. Approximately 30%-50% of individuals with PH1 respond to treatment with pyridoxine (vitamin B<sub>6</sub>, precursor to PLP) as defined by a greater than 30% reduction in urine oxalate concentration or normalization of urinary oxalate excretion after a minimum of three months of maximal therapy [<a class="bk_pop" href="#ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al 2014</a>]. <a class="bk_pop" href="#ph1.REF.monico.2005b.1704">Monico et al [2005b]</a> showed that the presence of the <i>AGXT</i> mistargeting <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a> was associated with pyridoxine responsiveness; homozygotes showed normalization or near-normalization of urine oxalate concentration (&#x0003c;0.5-0.7 mmol/1.73 m<sup>2</sup>/day) and compound heterozygotes demonstrated a partial reduction in urine oxalate concentration by at least 30% of prior documented levels. The same result has been seen in individuals with at least one <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Phe152Ile</a> pathogenic variant.</p><p><a class="bk_pop" href="#ph1.REF.fargue.2013b.1776">Fargue et al [2013b]</a> demonstrated that pyridoxine increased peroxisomal import of AGT in individuals with PH1 with a <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; pyridoxine also increased expression and catalytic activity of the mutated AGT. These findings suggest potential beneficial effects in individuals with pathogenic variants that do not result in mistargeting of enzyme to the mitochondria. Accordingly, all individuals with PH1 should undergo a trial of pharmacologic-dose pyridoxine at the time of diagnosis to assess responsivenes &#x02013; including individuals with ESRD requiring dialysis. Pyridoxine treatment is particularly important in pyridoxine-responsive individuals on dialysis since it is the only treatment currently available that can reduce hepatic oxalate production.</p><p>Most pyridoxine-responsive individuals show maximum benefit at 5-8 mg/kg/day [<a class="bk_pop" href="#ph1.REF.monico.2005a.183">Monico et al 2005a</a>, <a class="bk_pop" href="#ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al 2014</a>], though some have required a higher dose [<a class="bk_pop" href="#ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al 2014</a>]. A starting dose of 5 mg/kg/day is recommended. Response should be measured by comparison of the 24-hour urine oxalate excretion rate before treatment with the oxalate excretion rate after three to six months of pyridoxine treatment. It is important that pyridoxine be continued during the follow-up urine collection. Stepwise increases to a maximum of 10-20 mg/kg/day with assessments of response at each step is appropriate to determine effectiveness. If the individual is responsive, this approach also facilitates identification of lowest dose at which maximum response occurs. Several authors have noted little additional benefit at doses &#x0003e;10 mg/kg/day [<a class="bk_pop" href="#ph1.REF.bobrowski.2008.152">Bobrowski &#x00026; Langman 2008</a>, <a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>]. Pyridoxine response can be difficult to ascertain in individuals with advanced CKD and ESRD since urinary oxalate excretion rates may be influenced by the low GFR. In individuals with GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup>, changes in plasma oxalate may be valuable in assessing response.</p><p>Individuals responsive to pyridoxine should continue this therapy indefinitely or until after orthotopic liver transplantation when normal enzyme has replaced deficient AGT. Blood levels of pyridoxine, measured as its metabolite pyridoxal phosphate, may be followed in individuals to ensure that adequate absorption is occurring [<a class="bk_pop" href="#ph1.REF.harambat.2011.864580">Harambat et al 2011</a>], though correlation between blood levels and urine oxalate response was not observed in a recent study [<a class="bk_pop" href="#ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn et al 2014</a>].</p><p>Peripheral neuropathy has been reported in individuals who do not have PH1 who were receiving very large doses of pyridoxine (typically, adults receiving 1-2 g/day). However, pyridoxine has demonstrated an excellent safety profile in individuals with PH1, even after decades of use. Paresthesias, a known complication of large doses of pyridoxine [<a class="bk_pop" href="#ph1.REF.toussaint.1998.49">Toussaint 1998</a>], have only been reported in one individual on a dose of 2.1 mg/kg/day and resolved following discontinuation of the drug.</p></div><div id="ph1.Dialysis"><h4>Dialysis</h4><p>The issues related to the removal of oxalate and current modalities of dialysis are complex. Interested readers are directed to papers outlining the specific details of extracorporeal removal of oxalate [<a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>, <a class="bk_pop" href="#ph1.REF.plumb.2013.1155">Plumb et al 2013</a>, <a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>]. Oxalate removal is much more effective with hemodialysis than peritoneal dialysis. For that reason, peritoneal dialysis should not be relied on as the primary dialysis modality in any individual with PH1.</p><p>In brief, despite the small size of the oxalate molecule (90 daltons), the rate of oxalate production in persons with PH1-related ESRD (frequently 2-7 mmol/1.73 m<sup>2</sup>/day) vastly surpasses the ability to remove it via conventional dialysis. The sequestration of oxalate in tissue compartments outside the vascular space makes it difficult to effectively remove it from the body. Current guidelines suggest that the intent of dialysis is to reduce and maintain the plasma oxalate level below 30-45 &#x000b5;mol/L (the calcium/oxalate supersaturation threshold at which tissue deposition occurs) as much of the time between dialysis sessions as possible.</p><p>While more aggressive strategies using high-flux dialyzers, daily hemodialysis, combined hemodialysis and peritoneal dialysis, hemodiafiltration, and even charcoal perfusion have all been reported [<a class="bk_pop" href="#ph1.REF.plumb.2013.1155">Plumb et al 2013</a>, <a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>], the end result is that while plasma removal rates of oxalate can be achieved in the range of greater than 60%, the total body store of oxalate rebounds to a level of 80% of the predialysis levels within 24 hours of the last hemodialysis session.</p><p>A case report of one individual treated with aggressive hemodialysis (8-10 hrs, 7 nights/wk) does suggest that this level of intense dialysis allows for maintenance of the predialysis oxalate levels at or just below the tissue saturation point (30-45 &#x000b5;mol/L) [<a class="bk_pop" href="#ph1.REF.plumb.2013.1155">Plumb et al 2013</a>]. In most individuals with PH1, four or more dialysis sessions per week are needed to maintain predialysis plasma oxalate concentrations in a range to minimize risk of oxalosis [<a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>]. Since oxalate production varies significantly among individuals with PH1, it is important that dialysis prescriptions are individualized [<a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>]. In addition, continuous dialytic therapies such as continuous veno-venous hemodialysis can maintain plasma oxalate below 20 &#x003bc;mol/L for prolonged periods and may be useful in acute situations such as following transplantation in an individual with extensive oxalosis whose kidney allograft is functioning poorly.</p><p>Though dialysis is most often used as a bridge to transplantation, it may also be needed as an adjunct therapy to decrease oxalate burden in the presence of delayed or poor renal function after liver/kidney transplantation, in older individuals if liver/kidney transplantation is not deemed an option, and in countries with no access to organ transplantation.</p></div><div id="ph1.Organ_Transplantation"><h4>Organ Transplantation</h4><p>As dialysis cannot prevent systemic oxalosis in an individual with a GFR &#x0003c;25-30 mL/min/1.73 m<sup>2</sup>, organ transplantation is the preferred option for treatment. The reader is encouraged to review the best practice recommendations on organ transplant of non-pyridoxine-sensitive individuals with PH1 [<a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>]. These guidelines take into consideration the individual's age, residual GFR, and evidence of systemic oxalate deposition in extrarenal organs.</p><p>The percentage of survivors after liver-kidney transplant surpasses the percentage of survivors after isolated kidney transplant: adult five-year survival percentage for individuals after kidney vs dual transplant are 45% vs 67% [<a class="bk_pop" href="#ph1.REF.bergstralh.2010.2493">Bergstralh et al 2010</a>]; those for children are 14% vs 76% [<a class="bk_pop" href="#ph1.REF.harambat.2012.458">Harambat et al 2012</a>].</p><p>Isolated liver transplant may be considered in an individual with significant residual renal function (e.g., GFR &#x0003e;60 mL/min/1.73 m<sup>2</sup>), with the presumption that decline in renal function will be arrested and only a single organ transplant required. However, the concerns regarding the risks of liver transplant, the uncertain and often slow rate of decline in renal function, and emerging novel treatments for PH1 are such that most experts defer the decision to proceed until dual transplantation is required.</p><p>Most of the published literature includes reports of transplants using organs from deceased donors; however, living/living related donation of a split liver graft (if the recipient is small enough) and/or living donor kidney or liver allografts are viable alternatives in some situations. It is important to note that the appropriateness of using a parent or sib who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as a donor remains unclear. Heterozygotes can have reduced AGT enzyme activity in the liver, though they typically have normal urine oxalate excretion and remain free of stones or oxalate-related CKD.</p><p>It is believed that simultaneous liver/kidney transplant is the most logical for any adult or child with CKD Category 4 or below, given the need for renal function to excrete the body burden of oxalate. However, if the wait for a suitable liver graft will significantly delay transplantation, simultaneous liver/kidney transplant may not be the best option for individuals with CKD Category 5 or on dialysis, as they often face severe oxalate burden that can overwhelm a new renal graft and lead to graft failure caused by oxalate stones/deposition. The choice in such individuals, most often small children/infants where anatomy may preclude a simultaneous approach, is to proceed with sequential (i.e., liver followed by kidney) transplantation.</p><p>It is also important to note that in all forms of transplantation, mobilization of systemic oxalate places the renal allograft at risk until tissue oxalate stores are completely cleared. For this reason, both liver and kidney transplant recipients must be monitored closely following transplantation with maintenance of high urine volume and crystal inhibitor medication, and even dialyzed following surgery if delayed or otherwise compromised kidney allograft function results in high plasma oxalate levels. In the post-kidney- and/or liver-transplant period, daily hemodialysis should be maintained until the renal clearance of oxalate maintains plasma oxalate well below 30 &#x003bc;mol/L, in order to minimize risk of oxalate nephropathy. It is important to note that complete clearance of tissue oxalate stores by a well-functioning renal allograft requires several months to more than five years following successful liver transplantation [<a class="bk_pop" href="#ph1.REF.monico.2001.954">Monico &#x00026; Milliner 2001</a>, <a class="bk_pop" href="#ph1.REF.tang.2014.376">Tang et al 2014</a>] and is confirmed by sustained normalization of urine oxalate excretion. Pyridoxine supplementation can be discontinued at the time of liver transplantation, since normal AGT activity will have been restored.</p></div></div><div id="ph1.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Recommendations can all be found in <b>Treatment of Manifestations</b>, specifically in the subsections on <a href="#ph1.Reduction_of_Urinary_Calcium_Oxalate">Reduction of Calcium Oxalate Supersaturation</a> and <a href="#ph1.Reduction_of_Oxalate_Biosynthesis">Reduction of Oxalate Biosynthesis</a>.</p></div><div id="ph1.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Secondary complications arising as a result of systemic oxalosis are an increasing risk as GFR declines. Thus, careful monitoring of kidney function is essential. Recommendations for prevention of secondary complications can be found in the sections on <b>Surveillance</b> and <b>Treatment of Manifestations</b> (<a href="#ph1.Dialysis">Dialysis</a> and <a href="#ph1.Organ_Transplantation">Organ Transplantation</a>). See <a href="#ph1.Clinical_Description">Clinical Description</a>, <b>Oxalosis</b>, for a description of the broad range of tissues and organs that suffer consequences of oxalosis. Regular dental care and ophthalmologic follow up should be part of management in individuals with reduced GFR.</p></div><div id="ph1.Surveillance"><h3>Surveillance</h3><p>Individuals with PH type 1 require lifelong surveillance, the frequency of which is related to kidney function [<a class="bk_pop" href="#ph1.REF.hoppe.2009.1264">Hoppe et al 2009</a>, <a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>, <a class="bk_pop" href="#ph1.REF.cochat.2013.649">Cochat &#x00026; Rumsby 2013</a>].</p><ul><li class="half_rhythm"><div>Individuals with preserved renal function (i.e., measured or estimated GFR &#x0003e;60 mL/min/1.73 m<sup>2</sup>) require the following to evaluate/ensure treatment efficacy:</div><ul><li class="half_rhythm"><div>Regular monitoring of kidney function. Serum creatinine for determination of eGFR should be performed at least annually and more frequently in children and adolescents and in individuals with changing kidney function or clinically active stone disease.</div></li><li class="half_rhythm"><div>Regular renal ultrasound examinations to monitor and manage stone forming activity</div></li><li class="half_rhythm"><div>Urinalysis and measurements of urine oxalate excretion, urine volume, and calcium oxalate saturation (spot and 24-hour collections)</div></li><li class="half_rhythm"><div>Periodic fundoscopic eye examination to identify the extent of any oxalate deposition</div></li></ul></li><li class="half_rhythm"><div>When GFR is known to be reduced to &#x0003c;60 mL/min/1.73 m<sup>2</sup> plasma oxalate concentration should be measured and monitored regularly (at least annually or more often as indicated by the clinical course) in addition to the above evaluations. More frequent monitoring of kidney function is indicated.</div></li><li class="half_rhythm"><div>Individuals with a GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup> or a rapid deterioration in function should have the above evaluations as well as the following testing (performed prior to initiation of dialysis if possible, and repeated as needed):</div><ul><li class="half_rhythm"><div>Frequent assessment of serum creatinine and plasma oxalate, typically at least monthly or more often depending on clinical circumstances</div></li><li class="half_rhythm"><div>X-ray examination of the long bones to evaluate for radiodense metaphyseal bands and diffuse demineralization. Bone marrow examination may also be required.</div></li><li class="half_rhythm"><div>Electrocardiogram to evaluate for an associated atrioventricular block or other oxalate related conduction abnormalities</div></li><li class="half_rhythm"><div>Echocardiogram for evidence of oxalate cardiomyopathy</div></li><li class="half_rhythm"><div>Hemoglobin to evaluate for anemia associated with either renal dysfunction or marrow deposition of oxalate</div></li><li class="half_rhythm"><div>History and physical examination to assess the risk of arterial insufficiency or ischemia based on vessel wall deposition</div></li><li class="half_rhythm"><div>Thyroid function testing</div></li><li class="half_rhythm"><div>Frequent clinical evaluation to monitor for additional complications of oxalosis (see <a href="#ph1.Clinical_Description">Clinical Description</a>, <b>Oxalosis</b>) &#x02013; noting that at GFR &#x0003c;30 mL/min/1.73 m<sup>2</sup> the ongoing deposition of tissue oxalate (oxalosis) will predispose all individuals to multiorgan involvement, and this will worsen/accelerate as the person enters ESRD and initiates dialysis.</div></li></ul></li></ul><p>Note: Investigations should occur more often in newly diagnosed symptomatic individuals or in children younger than age two to three years.</p></div><div id="ph1.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Intravascular volume depletion. The importance of maintaining dilute urine <b>cannot</b> be overemphasized.</div></li><li class="half_rhythm"><div>Intake of vitamin C that exceeds the recommended daily allowance</div></li><li class="half_rhythm"><div>Loop diuretics to maintain dilute urine, as they can lead to hypercalciuria and increase the production of calcium oxalate stones</div></li><li class="half_rhythm"><div>High doses of nonsteroidal anti-inflammatory medications or any pharmacologic agent that can compromise kidney function</div></li><li class="half_rhythm"><div>Large intake of foods high in oxalate (e.g., chocolate, rhubarb, starfruit)</div></li></ul></div><div id="ph1.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate all at-risk family members, whether or not they are symptomatic, in order to identify those individuals who would benefit from early treatment, monitoring, and preventive intervention [<a class="bk_pop" href="#ph1.REF.cochat.2012.1729">Cochat et al 2012</a>]. If the <i>AGXT</i> pathogenic variants in the family are known, the genetic status of at-risk family members can be clarified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. The benefits of early initiation of conservative measures cannot be ignored [<a class="bk_pop" href="#ph1.REF.chand.2009.670">Chand &#x00026; Kaskel 2009</a>, <a class="bk_pop" href="#ph1.REF.fargue.2009.767">Fargue et al 2009</a>, <a class="bk_pop" href="#ph1.REF.mart_n.2011.227">Mart&#x000ed;n et al 2011</a>].</p><p>Asymptomatic individuals found to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>AGXT</i> pathogenic variants are at risk for stones and kidney damage and should be managed according to the same guidelines as those who present with symptoms.</p><p>See <a href="#ph1.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ph1.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy does not appear to be an important risk factor for the development of ESRD in the majority of women with PH1 [<a class="bk_pop" href="#ph1.REF.norby.2004.277">Norby &#x00026; Milliner 2004</a>]; however, women in whom renal function deteriorated during the pregnancy and remained abnormal post delivery have been reported [<a class="bk_pop" href="#ph1.REF.cimino.2005.341">Cimino et al 2005</a>]. Maintenance of adequate fluid intake throughout pregnancy can be challenging, especially during the first trimester, and in some with hyperemesis gravidarum intravenous fluid administration may be required. Continuation of pyridoxine (for pyridoxine-sensitive individuals) and careful monitoring of kidney function and stones throughout pregnancy and the early postpartum period are important to good outcomes.</p><p>Women with PH1 have had successful pregnancies following liver/kidney transplantation. In one woman liver function was apparently preserved, but renal graft function declined transiently after the birth of her first child and permanently after the birth of her second child [<a class="bk_pop" href="#ph1.REF.pruvot.1997.615">Pruvot et al 1997</a>].</p><p>Of particular note, pregnant women with PH1 warrant close monitoring during pregnancy and the postpartum period by both an obstetrician and nephrologist.</p><p>Generally, the offspring of women with PH1 have done well [<a class="bk_pop" href="#ph1.REF.norby.2004.277">Norby &#x00026; Milliner 2004</a>].</p></div><div id="ph1.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several novel therapies are under investigation.</p><div id="ph1.OxalateDegrading_Bacteria"><h4>Oxalate-Degrading Bacteria</h4><p>Oral administration of bacteria such as <i>Oxalobacter formigenes</i> (<i>O. formigenes</i>) or lactic acid bacteria to degrade oxalate and reduce the amount of oxalate available for intestinal absorption [<a class="bk_pop" href="#ph1.REF.azcarateperil.2006.1891">Azcarate-Peril et al 2006</a>, <a class="bk_pop" href="#ph1.REF.ivanovski.2013.998">Ivanovski &#x00026; Dr&#x000fc;eke 2013</a>] is being investigated. <i>O. formigenes</i> shows the most promise as a potential therapy for the hyperoxalurias. Although it is a normal component of the intestinal flora, many individuals do not maintain colonization. <i>O. formigenes</i> is also thought to stimulate secretion of endogenous oxalate into the intestine for its own metabolic use [<a class="bk_pop" href="#ph1.REF.hatch.2006.691">Hatch et al 2006</a>, <a class="bk_pop" href="#ph1.REF.hatch.2008.143">Hatch &#x00026; Freel 2008</a>, <a class="bk_pop" href="#ph1.REF.arvans.2017.876">Arvans et al 2017</a>]. A human strain of <i>O. formigenes</i> (HC-1) has been shown to promote oxalate secretion into the intestine of a mouse model of primary hyperoxaluria [<a class="bk_pop" href="#ph1.REF.hatch.2013.379">Hatch &#x00026; Freel 2013</a>]. Administration of the HC-1 strain reduced the amount of oxalate excreted via the kidney. Despite these findings in animal studies, and promising early findings in pilot studies in individuals with PH [<a class="bk_pop" href="#ph1.REF.hoppe.2006.1305">Hoppe et al 2006</a>], three double-blind, placebo-controlled trials of <i>O. formigenes</i> administered orally to individuals with PH have failed to show benefit [<a class="bk_pop" href="#ph1.REF.hoppe.2011.3609">Hoppe et al 2011</a>, <a class="bk_pop" href="#ph1.REF.hoppe.2017.781">Hoppe et al 2017</a>, <a class="bk_pop" href="#ph1.REF.milliner.2018.313">Milliner et al 2018</a>]</p><p>In a different approach, a crystalline-stabilized oxalate-degrading enzyme administered orally has been used successfully in an <i>Agxt</i> knockout mouse model system of PH1. Urinary oxalate was reduced and in the mice receiving the highest dose, there was complete protection against urolithiasis and nephrocalcinosis [<a class="bk_pop" href="#ph1.REF.grujic.2009.86">Grujic et al 2009</a>]. To date, there have been no clinical studies of oxalate-degrading enzyme in individuals with PH.</p></div><div id="ph1.Gene_Modification"><h4>Gene Modification</h4><p>A variety of strategies are currently being explored.</p><p><a class="bk_pop" href="#ph1.REF.salido.2011.870">Salido et al [2011]</a> have demonstrated successful replacement of AGT enzyme activity in the livers of a knockout mouse model of PH1 utilizing a somatic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> transfer via two adeno-associated viral vectors. However, applicability of these approaches to treatment of individuals with PH1 will be challenging. Limitations include transduction efficiency (due to the need to modify a significant proportion of liver cells), loss of target expression over time, and potential adverse effects of viral vectors. An alternative strategy is coupling of functional AGT to a PEG-PGA polymer which will target the enzyme to the peroxisomes of hepatic cells [<a class="bk_pop" href="#ph1.REF.roncador.2017.897">Roncador et al 2017</a>]. This approach is currently in early stages of exploration.</p><p>Pluripotent cells induced from leukocytes or fibroblasts from individuals with PH1 could potentially be genetically modified to contain normal <i>AGXT</i>. If the genetically modified cells were then differentiated in vitro into hepatocytes, they could theoretically be used for autotransplantation to repopulate the liver of the cell donor with AGT-competent cells. Zapata-Linares and colleagues recently described an early step in this process in which they were able to generate pluripotent stem cells from an individual with PH1 with the <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Ile244Thr</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ph1.REF.zapatalinares.2016.116">Zapata-Linares et al 2016</a>]. While autotransplantation of cells could bypass the immune barrier of hepatocyte transplantation, considerable work remains to establish this as viable treatment.</p></div><div id="ph1.Small_Molecule_Therapies"><h4>Small Molecule Therapies</h4><p>Chemical chaperones facilitate folding of newly translated proteins offering protection from cellular quality-control degradative processes. Stabilization of AGT with a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may permit the protein to achieve a folded state with some degree of enzymatic activity [<a class="bk_pop" href="#ph1.REF.danpure.2005a.1525">Danpure 2005a</a>, <a class="bk_pop" href="#ph1.REF.danpure.2005b.303">Danpure 2005b</a>]. In PH1 specifically, this type of effect has been demonstrated in vitro for both mistargeting variants and AGT variants that induce aggregation/accelerated degradation [<a class="bk_pop" href="#ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</a>, <a class="bk_pop" href="#ph1.REF.hopper.2008.30493">Hopper et al 2008</a>]. Chemical chaperones may have general stabilizing functions or they may be designed to target proteins with specific pathogenic variants. Missense pathogenic variants that do not cause loss of protein stability are not suitable candidates for this pharmacogenetic approach; nor are insertions, deletions, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, or splice junction changes, which usually do not produce a protein product.</p><p>Pyridoxine, commonly used in treatment of PH1, has been shown in vitro to act as a chemical chaperone increasing AGT expression and correcting peroxisomal targeting in cells with three common pathogenic variants <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a>, <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Phe152Ile</a>, and <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Ile244Thr</a> [<a class="bk_pop" href="#ph1.REF.fargue.2013a.2475">Fargue et al 2013a</a>, <a class="bk_pop" href="#ph1.REF.fargue.2013b.1776">Fargue et al 2013b</a>, <a class="bk_pop" href="#ph1.REF.cellini.2014.158">Cellini et al 2014</a>].</p><p>Dequalinium chloride has been shown in vitro to rescue AGT mistargeting defects caused by the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Gly170Arg [<a class="bk_pop" href="#ph1.REF.miyata.2014.14406">Miyata et al 2014</a>] by blocking import into mitochondria. No clinical trials of this agent have been reported. High throughput methods are now being used to screen for other compounds with AGT chaperone effects.</p><p>Pyridoxamine, a drug explored as therapy for human diabetic nephropathy, has been shown in a CHO cell model for PH1 to be more effective than pyridoxine in rescuing folding-defective variants of human AGT causing PH1 [<a class="bk_pop" href="#ph1.REF.oppici.2015.5500">Oppici et al 2015</a>]. In addition, pyridoxamine has been hypothesized to trap metabolic precursors of oxalate, glycoaldehyde, and glyoxylate [<a class="bk_pop" href="#ph1.REF.chetyrkin.2005.53">Chetyrkin et al 2005</a>]. Animal studies have shown 50% reduction of urinary oxalate excretion in an ethylene glycol model of hyperoxaluria [<a class="bk_pop" href="#ph1.REF.chetyrkin.2005.53">Chetyrkin et al 2005</a>, <a class="bk_pop" href="#ph1.REF.scheinman.2005.368">Scheinman et al 2005</a>]. A proposed clinical trial in hyperoxaluric stone formers and individuals with PH was withdrawn prior to enrollment (<a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>).</p></div><div id="ph1.Manipulation_of_the_Metabolic_Pathwa"><h4>Manipulation of the Metabolic Pathway</h4><p><b>Substrate reduction</b> targets precursors in the metabolic pathway, reducing them and thus preventing their eventual metabolism to oxalate. Hydroxyproline is found in the diet as well as derived from normal bone turnover. Intravenous infusion of hydroxyproline labeled with a stable isotope demonstrated that its metabolism contributes 17% of the oxalate in urine in individuals with PH1, while it contributes 46% and 33% in individuals with PH2 and PH3, respectively. Thus hydroxyproline reduction would appear more valuable in forms of PH other than PH1 [<a class="bk_pop" href="#ph1.REF.fargue.2018.1615">Fargue et al 2018</a>].</p><p>L-2-oxothiazolindine-4-carboxylate (OTZ) is converted in tissues to cysteine, forms an adduct with glyoxylate, and has been shown to reduce urine oxalate in healthy subjects. Though its administration to two individuals with PH1 led to a slight reduction in plasma oxalate, there was no change in urine oxalate in these individuals [<a class="bk_pop" href="#ph1.REF.holmes.2001a.858">Holmes et al 2001a</a>].</p><p>An <i>Agxt</i> knockout mouse model has been developed to explore the effects of substrate depletion and to clarify the various adjustments in the metabolic pathway that result from absence of AGT [<a class="bk_pop" href="#ph1.REF.hern_ndezfernaud.2010.4766">Hern&#x000e1;ndez-Fernaud &#x00026; Salido 2010</a>, <a class="bk_pop" href="#ph1.REF.knight.2012.f688">Knight et al 2012</a>]. A model system developed in CHO cells uses stable transfection with all combinations of recombinant genes that encode glycolate oxidase, glyoxylate reductase, and AGT, allowing investigation of the interaction of these enzymes and the effects of deficiencies of one or more enzymes [<a class="bk_pop" href="#ph1.REF.behnam.2006.409">Behnam et al 2006</a>].</p><p>Glycolate is converted to glyoxylate by glycolate oxidase. The glycolate oxidase inhibitor CPPST has been shown to significantly reduce oxalate production in Agxt1<sup>-/-</sup> hepatocytes; when administered orally, Agxt1<sup>-/-</sup> knockout mice reduced urine oxalate by 30%-50% [<a class="bk_pop" href="#ph1.REF.martinhigueras.2016.719">Martin-Higueras et al 2016</a>]. RNA inhibition (Dicer-siRNA) targeting hydroxyacid oxidase 1 (<i>HAO1</i>) messenger RNA, which encodes glycolate oxidase, normalized oxalate production in hepatocytes of <i>AGXT</i> knockout mice [<a class="bk_pop" href="#ph1.REF.dutta.2016.770">Dutta et al 2016</a>]. siRNA inhibition of GO is now in Phase I/II clinical trials in individuals with PH1. Implications of the expected increase in glycolate in individuals with PH1 treated with this agent remain to be evaluated [<a class="bk_pop" href="#ph1.REF.milliner.2016.666">Milliner 2016</a>].</p><p>Inhibition of LDH activity is another logical target since formation of oxalate from glyoxylate could potentially be prevented. Therapeutic reduction of LDH activity through technologies such as siRNA are in early stages of exploration.</p></div><div id="ph1.Hepatocyte_Transplantation"><h4>Hepatocyte Transplantation</h4><p>Repopulation of the liver of an individual with PH1 with normal or genetically corrected hepatocytes is less invasive than liver transplantation. However, host cells must be ablated as they would continue to produce oxalate and the donor hepatocytes would then require a growth advantage to achieve repopulation. This approach has been explored in a mouse model of PH1 [<a class="bk_pop" href="#ph1.REF.guha.2005.161">Guha et al 2005</a>, <a class="bk_pop" href="#ph1.REF.jiang.2008.1253">Jiang et al 2008</a>]. <a class="bk_pop" href="#ph1.REF.koul.2005.176">Koul et al [2005]</a> transfected <i>AGXT</i> (genetically engineered for selective peroxisomal delivery) into cultured human hepatocytes by amplifying the <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> and using liposomal transfection techniques. They demonstrated high efficiency of transfection and appropriate intracellular localization to peroxisomes [<a class="bk_pop" href="#ph1.REF.koul.2005.176">Koul et al 2005</a>].</p><p>Liver cell transplantation was reported in a girl age 15 months with PH1 as a potential bridge to orthotopic liver transplant [<a class="bk_pop" href="#ph1.REF.beck.2012.2984">Beck et al 2012</a>]. The child tolerated both the cellular infusions and the immunosuppression. Initially no significant change was seen in plasma oxalate levels post infusion; however, the plasma oxalate levels slowly decreased over the ensuing two weeks. Long-term follow up (2-11 months) demonstrated levels of plasma oxalate that were significantly elevated (mean 80 &#x003bc;mol/L), though improved over baseline. Donor chimerism was not demonstrated during the protocol biopsy at five months nor at the time of liver harvest prior to the eventual orthotopic liver transplant.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ph1.Other"><h3>Other</h3><p><b>Auxiliary liver transplant.</b> Oxalate is an end product of metabolism that cannot be degraded by humans. Accordingly, elimination of all or a substantial portion of the native liver that is overproducting oxalate &#x02013; in addition to replacement of functional AGT enzyme &#x02013; is required [<a class="bk_pop" href="#ph1.REF.trotter.2014.241">Trotter &#x00026; Milliner 2014</a>]. Simply adding normal liver cells cannot reduce the oxalate overproduction of the AGT-deficient liver that remains. Though it is possible for some degree of hyperoxaluria caused by remaining native liver to be adequately tolerated, it increases long-term risk to the renal allograft and is further complicated in most circumstances by the hyperoxaluria that follows liver transplantation for months or years due to gradual mobilization of oxalate from tissue stores. For these reasons, the authors cannot recommend auxiliary liver transplantation in individuals with PH1.</p></div></div><div id="ph1.Genetic_Counseling"><h2 id="_ph1_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ph1.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Primary hyperoxaluria type 1 (PH1) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ph1.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a child <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with PH1 are presumed to be obligate heterozygotes (i.e., carriers of one <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Molecular genetic testing to confirm the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of both parents is appropriate.</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">At conception, each sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with PH1 has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div><div class="half_rhythm">In a very rare exception to this generalization, one individual with PH1 caused by maternal <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2 telomeric isodisomy has been reported. The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the common p.Lys12GlnfsTer156 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The mother was <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the variant; the variant was absent in the father [<a class="bk_pop" href="#ph1.REF.chevalierporst.2005.80">Chevalier-Porst et al 2005</a>]. This situation would alter the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The offspring of an individual with PH1 are typically obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AGXT</i>.</div><div class="half_rhythm">In a very rare exception to this generalization, one family with <a class="def" href="/books/n/gene/glossary/def-item/pseudodominant-inheritance/">pseudodominant inheritance</a> has been reported: offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with two variants on different alleles (<a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.[Gly170Arg];[Ser187Phe]</a>) and a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (<a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a>) were affected [<a class="bk_pop" href="#ph1.REF.hoppe.1997.36">Hoppe et al 1997</a>].</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="ph1.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives is most informative if the <i>AGXT</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. If the affected family member is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>AGXT</i>, <i>GRHPR</i>, and <i>HOGA1</i> can be considered.</p></div><div id="ph1.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ph1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ph1.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>AGXT</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical testing</b></p><ul><li class="half_rhythm"><div>Biochemical testing has been supplanted by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>Assay of AGT enzymatic activity prenatally is not generally offered because the enzyme is not expressed in amniocytes or chorionic villi and, thus, the assay of enzyme activity requires a fetal liver biopsy. AGT is not detectable in fetal liver until after 14 weeks' gestation [<a class="bk_pop" href="#ph1.REF.danpure.1989.271">Danpure et al 1989</a>].</div></li></ul><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate. Side effects of renal and/or liver transplantation and scarcity of suitable organs for transplantation may be a consideration for parents who already have one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child.</p></div></div><div id="ph1.Resources"><h2 id="_ph1_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=hyperoxaluriaprimary" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary hyperoxaluria</a></div></li><li class="half_rhythm"><div><b>Oxalosis &#x00026; Hyperoxaluria Foundation (OHF)</b></div><div>201 East 19th Street</div><div>Suite 12E</div><div>New York NY 10003</div><div><b>Phone:</b> 800-643-8699 (toll-free)</div><div><b>Email:</b> info@ohf.org</div><div><a href="http://www.ohf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ohf.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>Rare Kidney Stone Consortium Registry</b></div><div><b>Phone:</b> 800-270-4637 (toll-free)</div><div><b>Email:</b> hyperoxaluriacenter@mayo.edu</div><div><a href="http://www.mayo.edu/research/departments-divisions/department-internal-medicine/division-nephrology-hypertension/rare-kidney-stone-consortium-registry/rare-kidney-stone-consortium-registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rare Kidney Stone Consortium Registry</a></div></li></ul></div><div id="ph1.Molecular_Genetics"><h2 id="_ph1_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ph1.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Primary Hyperoxaluria Type 1: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1283/table/ph1.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph1.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ph1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ph1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ph1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ph1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ph1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ph1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ph1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/189" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>AGXT</i></a></td><td headers="hd_b_ph1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=189" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q37<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_ph1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Alanine-glyoxylate transaminase</td><td headers="hd_b_ph1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/AGXT" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AGXT database</a></td><td headers="hd_b_ph1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AGXT" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AGXT</a></td><td headers="hd_b_ph1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=AGXT[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AGXT</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ph1.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ph1.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Primary Hyperoxaluria Type 1 (<a href="/omim/259900,604285" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1283/table/ph1.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph1.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/259900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">259900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPEROXALURIA, PRIMARY, TYPE I; HP1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604285" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604285</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALANINE-GLYOXYLATE AMINOTRANSFERASE; AGXT</td></tr></tbody></table></div></div><div id="ph1.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>When alanine:glyoxylate aminotransferase (AGT) enzymatic activity is deficient, the substrate glyoxylate accumulates and is converted to oxalate by glycolate oxidase in peroxisomes or in the cytosol by lactate dehydrogenase [<a class="bk_pop" href="#ph1.REF.holmes.1998.1617">Holmes &#x00026; Assimos 1998</a>, <a class="bk_pop" href="#ph1.REF.danpure.2001">Danpure 2001</a>]. Oxalate forms insoluble calcium oxalate salts that the body cannot readily eliminate. In the most common pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">c.508G&#x0003e;A</a> (<a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a>), the AGT enzyme is mistargeted to the mitochondria rather than to the peroxisomes, where the substrate is localized. The mistargeted AGT enzyme retains substantial enzymatic activity but has no contact with its substrate, and thus the functional consequences are the same as for other pathogenic variants that result in no enzymatic activity. Mistargeting and high residual activity are seen in heterozygotes and homozygotes for the p.Gly170Arg variant [<a class="bk_pop" href="#ph1.REF.danpure.1998.8">Danpure 1998</a>, <a class="bk_pop" href="#ph1.REF.danpure.2001">Danpure 2001</a>]. (See <b>"Major" and "minor" AGXT alleles</b>.)</p><p><b>Gene structure.</b>
<i>AGXT</i> (<a href="/entrez/viewer.fcgi?val=NM_000030.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000030.2</a>) spans approximately 10 kb and comprises 11 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1283/#ph1.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>"Major" and "minor" <i>AGXT</i> alleles.</b> Two common normal alleles of <i>AGXT</i> are known: the most frequent is termed the "major <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>" (80% frequency in individuals of European origin) and the less frequent the "minor allele" (20% frequency in individuals of European origin, 2% in Japanese, 3% in South African blacks) [<a class="bk_pop" href="#ph1.REF.danpure.1994b.487">Danpure et al 1994b</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2003.44">Coulter-Mackie et al 2003</a>].</p><p>The major <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is the haplotype defined by the transcript variant <a href="/entrez/viewer.fcgi?val=NM_000030.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000030.2</a>, while the minor allele haplotype has two single amino acid substitutions, p.Pro11Leu and p.Ile340Met, among other <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> changes in strong disequilibrium [reviewed by <a class="bk_pop" href="#ph1.REF.pey.2013.687658">Pey et al 2013</a>].</p><p>In the minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the only normal allelic variant of functional significance is <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Pro11Leu</a>, which alters the amino acid sequence and creates a cryptic N-terminal mitochondrial targeting sequence [<a class="bk_pop" href="#ph1.REF.purdue.1991.10900">Purdue et al 1991</a>, <a class="bk_pop" href="#ph1.REF.fargue.2013a.2475">Fargue et al 2013a</a>]. The mitochondrial targeting sequence of the minor allele is functionally ineffective due to protein conformation; only about 5% of AGT encoded by the minor allele is found in the mitochondria (see <a class="bk_pop" href="#ph1.REF.pey.2013.687658">Pey et al [2013]</a> and references therein). However, certain pathogenic variants on the minor allele disrupt AGT folding, thereby unmasking the mitochondrial targeting signal, resulting in efficient mislocalization of AGT. Therefore, when in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration the minor allele acts synergistically with some pathogenic variants.</p><p>Other <i>AGXT</i> allelic haplotypes have been reported [<a class="bk_pop" href="#ph1.REF.danpure.1994a.55">Danpure et al 1994a</a>, <a class="bk_pop" href="#ph1.REF.tarn.1997.689">Tarn et al 1997</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2003.44">Coulter-Mackie et al 2003</a>]. These normal variants may be useful intragenic markers for determination of phase of pathogenic variants.</p><p><b>Pathogenic variants.</b> More than 190 <i>AGXT</i> pathogenic variants have been documented [<a class="bk_pop" href="#ph1.REF.williams.2009.910">Williams et al 2009</a>, <a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>]. Missense variants make up approximately 67% of PH1-causing variants [<a class="bk_pop" href="#ph1.REF.hopp.2015.2559">Hopp et al 2015</a>].</p><p>There are four common pathogenic variants and a few with ethnic associations. The other pathogenic variants have been detected just once or in small number of families.</p><p>The four common pathogenic variants p.Gly170Arg, p.Phe152Ile, and p.Ile244Thr (which occur on the minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> haplotype) and <a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">c.33dupC (p.Lys12GlnfsTer156)</a> (on the major allele haplotype) together account for more than 65% of PH1-causing alleles.</p><ul><li class="half_rhythm"><div>An <i>AGXT</i> minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> haplotype may exacerbate at least one copy of the <i>AGXT</i> minor allele with one of the following common pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration:</div><ul><li class="half_rhythm"><div class="half_rhythm"><a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Gly170Arg</a>, the most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, accounts for approximately one third of PH1-causing alleles. When in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration with the p.Pro11Leu variant of the minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, p.Gly170Arg slows the rate of dimerization of AGT monomers, exposing the cryptic mitochondrial targeting signal resulting in efficient import of monomers to the mitochrondrion, rather than to the peroxisome [<a class="bk_pop" href="#ph1.REF.lumb.1999.20587">Lumb et al 1999</a>, <a class="bk_pop" href="#ph1.REF.lumb.2000.36415">Lumb &#x00026; Danpure 2000</a>]. Denaturation studies support a destabilizing effect of p.Gly170Arg [<a class="bk_pop" href="#ph1.REF.cellini.2010a.1801">Cellini et al 2010a</a>]. Analysis of the crystal structure of AGT with p.Gly170Arg indicates significant local structural changes that may be associated with decreased protein stability [<a class="bk_pop" href="#ph1.REF.djordjevic.2010.233">Djordjevic et al 2010</a>].</div><div class="half_rhythm">In individuals with the p.Gly170Arg variant, the therapeutic response to pyridoxine is likely attributable at least in part to enhancement of the dimerization process by increased pyridoxal phosphate (PLP) [<a class="bk_pop" href="#ph1.REF.cellini.2011.1577">Cellini et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Phe152Ile</a>. When in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration with the p.Pro11Leu variant of the minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> haplotype, p.Phe152Ile is also associated with mitochondrial mistargeting. In the absence of saturating PLP, p.Phe152Ile is thought to monomerize and be susceptible to mistargeting [<a class="bk_pop" href="#ph1.REF.cellini.2009.8349">Cellini et al 2009</a>, <a class="bk_pop" href="#ph1.REF.cellini.2011.1577">Cellini et al 2011</a>, <a class="bk_pop" href="#ph1.REF.fargue.2013b.1776">Fargue et al 2013b</a>].</div><div class="half_rhythm">This is consistent with the positive response to pyridoxine in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with the p.Phe152Ile variant.</div></li><li class="half_rhythm"><div class="half_rhythm"><a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">p.Ile244Thr</a> appears to be the result of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> within the Canary Islands population [<a class="bk_pop" href="#ph1.REF.santana.2003.7277">Santana et al 2003</a>]. AGT with the p.Ile244Thr <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on the "minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>" apparently has an altered conformation [<a class="bk_pop" href="#ph1.REF.santana.2003.7277">Santana et al 2003</a>]. This variant is also apparently associated with mistargeting [<a class="bk_pop" href="#ph1.REF.fargue.2013a.2475">Fargue et al 2013a</a>].</div></li></ul></li><li class="half_rhythm"><div>On the <i>AGXT</i> major <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> haplotype:</div><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figph1Tagxtvariantsdiscussedinthisge" rid-ob="figobph1Tagxtvariantsdiscussedinthisge">c.33dupC (p.Lys12GlnfsTer156)</a>, the fourth common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, accounts for about 30% of PH1-causing alleles [<a class="bk_pop" href="#ph1.REF.coultermackie.2004.64">Coulter-Mackie et al 2004</a>]. This <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> occurs in a variety of ethnic groups and results in a frameshift that predicts <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>-mediated decay and deficiency of AGT.</div></li></ul></li></ul><p>Most <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have not had specific biochemical phenotypes associated with them other than degradation and loss of enzymatic activity [<a class="bk_pop" href="#ph1.REF.coultermackie.2006.349">Coulter-Mackie &#x00026; Lian 2006</a>]. The pathogenic mechanism of a few of the rarer missense variants is known:</p><ul><li class="half_rhythm"><div>p.Gly82Glu (on the major <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) apparently prevents binding of the essential cofactor pyridoxine (vitamin B<sub>6</sub>) [<a class="bk_pop" href="#ph1.REF.lumb.2000.36415">Lumb &#x00026; Danpure 2000</a>, <a class="bk_pop" href="#ph1.REF.cellini.2007.39">Cellini et al 2007</a>]. Rather than an intrinsic inability to bind PLP, this is now thought to be due to an altered binding state of PLP and the AGT-PMP intermediate [<a class="bk_pop" href="#ph1.REF.cellini.2011.1577">Cellini et al 2011</a>].</div></li><li class="half_rhythm"><div>p.Gly41Arg (on the minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) results in intraperoxisomal aggregation of AGT protein [<a class="bk_pop" href="#ph1.REF.danpure.1993.417">Danpure et al 1993</a>]. In vitro studies of Gly41 pathogenic variants demonstrate a propensity for aggregation particularly in the absence of bound PLP [<a class="bk_pop" href="#ph1.REF.cellini.2010b.2896">Cellini et al 2010b</a>, <a class="bk_pop" href="#ph1.REF.cellini.2011.1577">Cellini et al 2011</a>].</div></li><li class="half_rhythm"><div>p.Ser205Pro (on the major <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>) results in an unstable protein that is rapidly degraded [<a class="bk_pop" href="#ph1.REF.nishiyama.1993.1237">Nishiyama et al 1993</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</a>].</div></li></ul><p>In addition to the <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants and several small insertions and deletions are known (see databases in <a href="/books/NBK1283/#ph1.molgen.TA">Table A</a>; and <a class="bk_pop" href="#ph1.REF.coultermackie.2004.38">Coulter-Mackie &#x00026; Rumsby [2004]</a>, <a class="bk_pop" href="#ph1.REF.williams.2009.910">Williams et al [2009]</a>).</p><p>Large documented deletions that are typically detected by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> include:</p><ul><li class="half_rhythm"><div>Two deletions of the entire 5' one third to one half of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and contiguous upstream regions [<a class="bk_pop" href="#ph1.REF.nogueira.2000.384">Nogueira et al 2000</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2001.314">Coulter-Mackie et al 2001</a>];</div></li><li class="half_rhythm"><div>Two other large intragenic deletions along with a third that extends into the 3' untranslated region [<a class="bk_pop" href="#ph1.REF.coultermackie.2005.172">Coulter-Mackie et al 2005</a>, <a class="bk_pop" href="#ph1.REF.monico.2007.1905">Monico et al 2007</a>, <a class="bk_pop" href="#ph1.REF.williams.2009.910">Williams et al 2009</a>];</div></li><li class="half_rhythm"><div>A telomeric <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2q encompassing <i>AGXT</i> [<a class="bk_pop" href="#ph1.REF.tammachote.2012.2124">Tammachote et al 2012</a>].</div></li></ul><div id="ph1.T.agxt_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>AGXT</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1283/table/ph1.T.agxt_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ph1.T.agxt_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Defines "minor <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>"</b></td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.32C&#x0003e;T</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro11Leu&#x000a0;<sup>1</sup></td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_4" rowspan="13" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000030.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000030<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000021.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000021<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1020A&#x0003e;G</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile340Met&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_1" rowspan="11" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.33dupC</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys12GlnfsTer156</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.121G&#x0003e;A</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly41Arg</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.245G&#x0003e;A</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly82Glu</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.454T&#x0003e;A</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe152Ile</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.466G&#x0003e;A</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly156Arg</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.508G&#x0003e;A</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly170Arg</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.560C&#x0003e;T</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser187Phe</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.613T&#x0003e;C</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser205Pro</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.697C&#x0003e;T</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg233Cys</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.731T&#x0003e;C</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile244Thr</td></tr><tr><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.738G&#x0003e;A</td><td headers="hd_h_ph1.T.agxt_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp246Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ph1.TF.4.1"><p class="no_margin">Two of the variants that define the haplotype of the minor <i>AGXT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> (<a href="/nuccore/115583676?report=genbank" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000030.2</a>) encodes a 392-amino-acid protein with a molecular mass of 43 kd. In humans, alanine:glyoxylate aminotransferase (AGT) is synthesized mainly in the liver and is normally located exclusively in the peroxisomes [<a class="bk_pop" href="#ph1.REF.danpure.2001">Danpure 2001</a>]. The enzyme is translated in the cytosol and transported into the peroxisomes. A C-terminal peroxisomal targeting signal is recognized by the peroxisomal receptor, Pex5p, allowing <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> into the peroxisome [<a class="bk_pop" href="#ph1.REF.fodor.2012.e1001309">Fodor et al 2012</a>]. AGT is a key enzyme in the detoxification of glyoxylate, converting glyoxylate to glycine [<a class="bk_pop" href="#ph1.REF.holmes.1998.1617">Holmes &#x00026; Assimos 1998</a>, <a class="bk_pop" href="#ph1.REF.danpure.2001">Danpure 2001</a>]. In humans, glyoxylate is produced in the peroxisomes. PLP is an essential cofactor for AGT activity. The PLP site in AGT lies in a highly conserved amino acid sequence and is critical in the catalytic activity of the enzyme. The crystal structure of the normal AGT protein has been determined [<a class="bk_pop" href="#ph1.REF.zhang.2003.643">Zhang et al 2003</a>], allowing a delineation of the active site and the dimerization interface.</p><p>Note that <i>AGXT</i> encodes alanine:glyoxylate aminotransferase (AGT;<a href="http://enzyme.expasy.org/EC/2.6.1.44" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EC 2.6.1.44</a>), whose activity is largely confined to peroxisomes in the liver. This protein also shows serine:pyruvate aminotransferase activity (SPT;<a href="http://enzyme.expasy.org/EC/2.6.1.51" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EC 2.6.1.51</a>) (OMIM <a href="http://omim.org/entry/604285" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604285</a>). AGT and SPT are two separate enzymatic activities on the same protein coded by <i>AGXT</i>. AGT is the major activity; when it is deficient, PH1 results.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Approximately 50% of all individuals with PH1 show no AGT enzymatic activity and produce no immunologically detectable AGT protein.</p><p>Pathogenic variants resulting in <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> codons, frameshifts, partial <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, or splice junction variants are usually predicted to result in little or no functional protein.</p><p>Approximately 30% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals display a high level of residual AGT activity. Most of these individuals exhibit the mistargeting defect in which an otherwise functional AGT enzyme is synthesized in adequate amounts but is mislocalized to mitochondria instead of peroxisomes, where it is normally found and where the substrate glyoxylate remains. These individuals have classic PH1 despite the residual AGT enzymatic activity.</p><p>Pathogenic variants, apart from mistargeting ones, that cause true partial enzymatic activity appear to be rare but may be associated with late-onset or mild disease.</p><p>With many genetic diseases, it is now clear that a common consequence of pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants is protein misfolding and subsequent elimination by intracellular quality-control processes [<a class="bk_pop" href="#ph1.REF.waters.2001.57">Waters 2001</a>]. This biologic instability of protein carrying a missense change has been documented in p.Ser205Pro [<a class="bk_pop" href="#ph1.REF.nishiyama.1993.1237">Nishiyama et al 1993</a>] and with a variety of other pathogenic missense variants in AGT [<a class="bk_pop" href="#ph1.REF.coultermackie.2006.349">Coulter-Mackie &#x00026; Lian 2006</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</a>, <a class="bk_pop" href="#ph1.REF.hopper.2008.30493">Hopper et al 2008</a>]. Biochemical studies of a broad range of individual pathogenic variants has revealed a diversity of effects both structural and functional, such as altered PLP or substrate binding, thermostability changes, altered interactions with peroxisomal targeting components, and misfolding with subsequent aggregation or degradation [<a class="bk_pop" href="#ph1.REF.cellini.2007.39">Cellini et al 2007</a>, <a class="bk_pop" href="#ph1.REF.cellini.2012.621">Cellini et al 2012</a>, <a class="bk_pop" href="#ph1.REF.fodor.2012.e1001309">Fodor et al 2012</a>, <a class="bk_pop" href="#ph1.REF.oppici.2012.132">Oppici et al 2012</a>, <a class="bk_pop" href="#ph1.REF.mesatorres.2013.e71963">Mesa-Torres et al 2013</a>, <a class="bk_pop" href="#ph1.REF.pey.2013.687658">Pey et al 2013</a>]. The findings may provide clues to potential therapeutic strategies as well as clues to the response to PLP. For instance, p.Gly82Glu has been demonstrated to have a reduced affinity for the pyridoxal phosphate cofactor [<a class="bk_pop" href="#ph1.REF.cellini.2007.39">Cellini et al 2007</a>].</p><p>It has been reported recently that the protein encoded by four pathogenic variants that occur on the minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (p.Gly170Arg, p.Ile244Arg, p.Phe152Ile, and p.Gly41Arg) undergo mistargeting [<a class="bk_pop" href="#ph1.REF.fargue.2013a.2475">Fargue et al 2013a</a>]. It is speculated that this is a common feature of variants occurring on the minor allele. Variant AGT proteins with p.Gly170Arg, p.Ile244Thr, p.Ile244Arg, or p.Phe162Ile are able to dimerize and are catalytically active, although functionally ineffective if located in the mitochondria. The variant p.Gly41Arg tends to aggregate and is inactive.</p><p>The effect of a given pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant may be exacerbated if it occurs on the AGT "minor <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>." In vitro studies have shown increased stability and enzymatic activity for some pathogenic variants when expressed on a "major allele" haplotype compared to a "minor allele" [<a class="bk_pop" href="#ph1.REF.williams.2007.1216">Williams &#x00026; Rumsby 2007</a>, <a class="bk_pop" href="#ph1.REF.coultermackie.2008.368">Coulter-Mackie &#x00026; Lian 2008</a>, <a class="bk_pop" href="#ph1.REF.williams.2009.910">Williams et al 2009</a>]. It has been speculated that some missense variants found on the "minor allele" in association with PH1 may not cause disease if they occurred on the major allele. However, some missense variants (e.g., p.Gly41Arg) found on both major and minor alleles cause disease in both instances.</p><p>The determination of a crystal structure for AGT [<a class="bk_pop" href="#ph1.REF.zhang.2003.643">Zhang et al 2003</a>] has permitted the rationalization of the functional consequences of selected <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic protein variants: p.Gly170Arg (mitochondrial mistargeting), p.Gly82Glu (prevention of cofactor binding), p.Gly41Arg (protein aggregation) [<a class="bk_pop" href="#ph1.REF.danpure.2004.e39">Danpure 2004</a>, <a class="bk_pop" href="#ph1.REF.danpure.2004.1">Danpure &#x00026; Rumsby 2004</a>, <a class="bk_pop" href="#ph1.REF.danpure.2006.1776">Danpure 2006</a>], p.Gly47Arg (affects dimerization), and p.Ser81Leu (no effect on dimerization) [<a class="bk_pop" href="#ph1.REF.robbiano.2010.667">Robbiano et al 2010</a>]. See <b>Pathogenic variants</b> for additional descriptions of abnormal proteins.</p></div></div><div id="ph1.References"><h2 id="_ph1_References_">References</h2><div id="ph1.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.alabadi.2013.1085">Al-Abadi E, Hulton SA. Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis--still the first choice? <span><span class="ref-journal">Pediatr Nephrol. </span>2013;<span class="ref-vol">28</span>:1085–9.</span> [<a href="/pubmed/23397522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23397522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.aleisa.2004.1788">Al-Eisa AA, Samhan M, Naseef M. End-stage renal disease in Kuwaiti children: an 8-year experience. <span><span class="ref-journal">Transplant Proc. </span>2004;<span class="ref-vol">36</span>:1788–91.</span> [<a href="/pubmed/15350478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15350478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.alfadhel.2012.373">Alfadhel M, Alhasan KA, Alotaibi M, Al Fakeeh K. Extreme intrafamilial variability of Saudi brothers with primary hyperoxaluria type 1. <span><span class="ref-journal">Ther Clin Risk Manag. </span>2012;<span class="ref-vol">8</span>:373–6.</span> [<a href="/pmc/articles/PMC3431957/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3431957</span></a>] [<a href="/pubmed/22956877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22956877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.arvans.2017.876">Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, Karrar E, Roy-Chowdhury J, Musch M, Asplin J, Chang E, Hassan H. Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. <span><span class="ref-journal">J Am Soc Nephrol. </span>2017;<span class="ref-vol">28</span>:876–87.</span> [<a href="/pmc/articles/PMC5328155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5328155</span></a>] [<a href="/pubmed/27738124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27738124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.asplin.2007.565">Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. <span><span class="ref-journal">J Urol. </span>2007;<span class="ref-vol">177</span>:565–9.</span> [<a href="/pubmed/17222634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17222634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.azcarateperil.2006.1891">Azcarate-Peril MA, Bruno-Barcena JM, Hassan HM, Klaenhammer TR. Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from Lactobacillus acidophilus. <span><span class="ref-journal">Appl Environ Microbiol. </span>2006;<span class="ref-vol">72</span>:1891–9.</span> [<a href="/pmc/articles/PMC1393175/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1393175</span></a>] [<a href="/pubmed/16517636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16517636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.beck.2006.984">Beck BB, Hoppe B. Is there a genotype-phenotype correlation in primary hyperoxaluria type1? <span><span class="ref-journal">Kidney Int. </span>2006;<span class="ref-vol">70</span>:984–6.</span> [<a href="/pubmed/16957746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16957746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.beck.2012.2984">Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber F, Goebel H, Salido EC, Kemper M, Meyburg J, Hoppe B. Liver cell transplantation in severe infantile oxalosis &#x02013; a potential bridging procedure to orthotopic liver transplantation. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2012;<span class="ref-vol">27</span>:2984–9.</span> [<a href="/pubmed/22287658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22287658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.behnam.2006.409">Behnam JT, Williams EL, Brink S, Rumsby G, Danpure CJ. Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese hamster ovary cells. <span><span class="ref-journal">Biochem J. </span>2006;<span class="ref-vol">394</span>:409–16.</span> [<a href="/pmc/articles/PMC1408671/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1408671</span></a>] [<a href="/pubmed/16309382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16309382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.behnke.2001.2236">Behnke B, Kemper MJ, Kruse HP, M&#x000fc;ller-Wiefel DE. Bone mineral density in children with primary hyperoxaluria type I. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2001;<span class="ref-vol">16</span>:2236–9.</span> [<a href="/pubmed/11682674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11682674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.bergstralh.2010.2493">Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS. IPHR Investigators. Transplantation outcomes in primary hyperoxaluria. <span><span class="ref-journal">Am J Transplant. </span>2010;<span class="ref-vol">10</span>:2493–501.</span> [<a href="/pmc/articles/PMC2965313/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2965313</span></a>] [<a href="/pubmed/20849551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20849551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.berini.2015.449">Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. <span><span class="ref-journal">Muscle Nerve. </span>2015;<span class="ref-vol">51</span>:449–54.</span> [<a href="/pmc/articles/PMC4577279/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4577279</span></a>] [<a href="/pubmed/25363903" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25363903</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.bobrowski.2008.152">Bobrowski AE, Langman CB. The primary hyperoxalurias. <span><span class="ref-journal">Semin Nephrol. </span>2008;<span class="ref-vol">28</span>:152–62.</span> [<a href="/pubmed/18359396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18359396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.buchman.1995.24">Buchman AL, Moukarzel AA, Ament ME. Excessive urinary oxalate excretion occurs in long-term TPN patients both with and without ileostomies. <span><span class="ref-journal">J Am Coll Nutr. </span>1995;<span class="ref-vol">14</span>:24–8.</span> [<a href="/pubmed/7706606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7706606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.carrasco.2015.522">Carrasco A Jr, Granberg CF, Gettman MT, Milliner DS, Krambeck AE. Surgical management of stone disease in patients with primary hyperoxaluria. <span><span class="ref-journal">Urology. </span>2015;<span class="ref-vol">85</span>:522–6.</span> [<a href="/pmc/articles/PMC4559267/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4559267</span></a>] [<a href="/pubmed/25733260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25733260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2007.39">Cellini B, Bertoldi M, Montioli R, Paiardini A, Voltattorni C. Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications. <span><span class="ref-journal">Biochem J. </span>2007;<span class="ref-vol">408</span>:39–50.</span> [<a href="/pmc/articles/PMC2049084/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2049084</span></a>] [<a href="/pubmed/17696873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17696873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2010a.1801">Cellini B, Lorezetto A, Montioli R, Oppici E, Voltattorni CB. Human liver peroxisomal alanine:glyoxylate aminotransferase: Different stability under chemical stress of the major allele, the minor allele, and its pathogenic G170R variant. <span><span class="ref-journal">Biochimie. </span>2010a;<span class="ref-vol">92</span>:1801–11.</span> [<a href="/pubmed/20713123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20713123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2014.158">Cellini B, Montioli R, Oppici E, Astegno A, Voltattorni CB. The chaperone role of the pyridoxal 5'-phosphate and its implications for rare diseases involving B6-dependent enzymes. <span><span class="ref-journal">Clin Biochem. </span>2014;<span class="ref-vol">47</span>:158–65.</span> [<a href="/pubmed/24355692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24355692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2010b.2896">Cellini B, Montioli R, Paiardini A, Lorenzetto A, Maset F, Bellini T, Oppici E, Voltattorni CB. Molecular defects of the glycine 41 variants of alanine:glyoxylate aminotransferase associated with primary hyperoxaluria type 1. <span><span class="ref-journal">Proc Nat Acad Sci. </span>2010b;<span class="ref-vol">107</span>:2896–901.</span> [<a href="/pmc/articles/PMC2840350/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2840350</span></a>] [<a href="/pubmed/20133649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20133649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2009.8349">Cellini B, Montioli R, Paiardini A, Lorenzetto A, Voltatorni CB. Molecular insight into the synergism between the minor allele of human liver peroxisomal alanine:glyoxylate aminotransferase and the F152I mutation. <span><span class="ref-journal">J Biol Chem. </span>2009;<span class="ref-vol">284</span>:8349–58.</span> [<a href="/pmc/articles/PMC2659193/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2659193</span></a>] [<a href="/pubmed/19155213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19155213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2011.1577">Cellini B, Montioli R, Voltattorni CB. Human liver peroxisomal alanine:glyoxylate aminotransferase: characterization of the two allelic forms and their pathogenic variants. <span><span class="ref-journal">Biochim Biophys Acta. </span>2011;<span class="ref-vol">1814</span>:1577–84.</span> [<a href="/pubmed/21176891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21176891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cellini.2012.621">Cellini B, Oppici E, Paiardini A, Montioli R. Molecular insights into primary hyperoxaluria type 1 pathogenesis. <span><span class="ref-journal">Front Biosci (Landmark Ed). </span>2012;<span class="ref-vol">17</span>:621–34.</span> [<a href="/pubmed/22201765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22201765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.chand.2009.670">Chand AQ, Kaskel FJ. Timely diagnosis of primary hyperoxaluria type 1. <span><span class="ref-journal">Nat Rev Nephrol. </span>2009;<span class="ref-vol">5</span>:670–1.</span> [<a href="/pubmed/19935811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19935811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.chetyrkin.2005.53">Chetyrkin SV, Kim D, Belmont JM, Scheinman JI, Hudson BG, Voziyan PA. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. <span><span class="ref-journal">Kidney Int. </span>2005;<span class="ref-vol">67</span>:53–60.</span> [<a href="/pubmed/15610227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15610227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.chevalierporst.2005.80">Chevalier-Porst F, Rolland MO, Cochat P, Bozon D. Maternal isodisomy of the telomeric end of chromosome 2 is responsible for a case of primary hyperoxaluria type 1. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">132A</span>:80–3.</span> [<a href="/pubmed/15580638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15580638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cimino.2005.341">Cimino S, Ranno S, Garozzo M, Reggio M, Battaglia G, Maugeri O, Ventimiglia B. <span><span class="ref-journal">Minerva Urol Nefrol. </span>2005;<span class="ref-vol">57</span>:341–3.</span> [Primary hyperoxaluria and pregnancy] [<a href="/pubmed/16247357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16247357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cochat.2013.2273">Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. <span><span class="ref-journal">Pediatr Nephrol. </span>2013;<span class="ref-vol">28</span>:2273.</span> [<a href="/pubmed/23494551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23494551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cochat.2006.1075">Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO. Primary hyperoxaluria type 1: still challenging! <span><span class="ref-journal">Pediatr Nephrol. </span>2006;<span class="ref-vol">21</span>:1075–81.</span> [<a href="/pubmed/16810517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16810517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cochat.2012.1729">Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS. Primary hyerpoxaluria type 1: indications for screening and guidance for diagnosis and treatment. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2012;<span class="ref-vol">27</span>:1729–36.</span> [<a href="/pubmed/22547750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22547750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.cochat.2013.649">Cochat P, Rumsby G. Primary hyperoxaluria. <span><span class="ref-journal">New Engl J Med. </span>2013;<span class="ref-vol">369</span>:649–58.</span> [<a href="/pubmed/23944302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23944302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2005.264">Coulter-Mackie MB. Preliminary evidence for ethnic differences in primary hyperoxaluria type 1 genotype. <span><span class="ref-journal">Am J Nephrol. </span>2005;<span class="ref-vol">25</span>:264–8.</span> [<a href="/pubmed/15961945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15961945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2004.64">Coulter-Mackie MB, Applegarth D, Toone JR, Henderson H. The major allele of the alanine:glyoxylate aminotransferase gene: seven novel mutations causing primary hyperoxaluria type 1. <span><span class="ref-journal">Mol Genet Metab. </span>2004;<span class="ref-vol">82</span>:64–8.</span> [<a href="/pubmed/15110324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15110324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2008.368">Coulter-Mackie MB, Lian Q. Partial trypsin digestion as an indicator of mis-folding of mutant alanine:glyoxylate aminotransferase and chaperone effects of specific ligands. Study of a spectrum of missense mutants. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:368–74.</span> [<a href="/pubmed/18448374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18448374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2005.172">Coulter-Mackie MB, Lian Q, Applegarth D, Toone J. The major allele of the alanine:glyoxylate aminotransferase gene: nine novel mutations and polymorphisms associated with primary hyperoxaluria type 1. <span><span class="ref-journal">Mol Genet Metab. </span>2005;<span class="ref-vol">86</span>:172–8.</span> [<a href="/pubmed/15963748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15963748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2008.598">Coulter-Mackie MB, Lian Q, Applegarth D, Toone J, Waters PJ, Vallance H. Mutation-based diagnostic testing for primary hyperoxaluria type 1: survey of results. <span><span class="ref-journal">Clin Biochem. </span>2008;<span class="ref-vol">41</span>:598–602.</span> [<a href="/pubmed/18282470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18282470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2006.349">Coulter-Mackie MB, Lian Q. Consequences of missense mutations for dimerization and turnover of alanine:glyoxylate aminotransferase: Study of a spectrum of mutations. <span><span class="ref-journal">Mol Genet Metab. </span>2006;<span class="ref-vol">89</span>:349–59.</span> [<a href="/pubmed/16971151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16971151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2004.38">Coulter-Mackie MB, Rumsby G. Genetic heterogeneity in primary hyperoxaluria type 1: impact on diagnosis. <span><span class="ref-journal">Mol Genet Metab. </span>2004;<span class="ref-vol">83</span>:38–46.</span> [<a href="/pubmed/15464418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15464418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2001.314">Coulter-Mackie MB, Rumsby G, Applegarth DA, Toone JR. Three novel deletions in the alanine:glyoxylate aminotransferase gene of three patients with type 1 hyperoxaluria. <span><span class="ref-journal">Mol Genet Metab. </span>2001;<span class="ref-vol">74</span>:314–21.</span> [<a href="/pubmed/11708860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11708860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.coultermackie.2003.44">Coulter-Mackie MB, Tung A, Henderson HE, Toone JR, Applegarth DA. The AGT gene in Africa: a distinctive minor allele haplotype, a polymorphism (V326I), and a novel PH1 mutation (A112D) in Black Africans. <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">78</span>:44–50.</span> [<a href="/pubmed/12559847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12559847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.2004.e39">Danpure CJ. Molecular aetiology of primary hyperoxaluria type 1. <span><span class="ref-journal">Nephron Exp Nephrol. </span>2004;<span class="ref-vol">98</span>:e39–e44.</span> [<a href="/pubmed/15499210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15499210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.2006.1776">Danpure CJ. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. <span><span class="ref-journal">Biochim Biophys Acta. </span>2006;<span class="ref-vol">1763</span>:1776–84.</span> [<a href="/pubmed/17027096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17027096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.1998.8">Danpure CJ. The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1. <span><span class="ref-journal">J Nephrol. </span>1998;<span class="ref-vol">11</span>:8–12.</span> [<a href="/pubmed/9604801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9604801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.2001">Danpure CJ. Primary hyperoxaluria. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <em>The Metabolic and Molecular Bases of Inherited Disease.</em> Chap 133. 8 ed. New York, NY: McGraw-Hill. 2001:3323-67.</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.2005a.1525">Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? <span><span class="ref-journal">Nephrol Dial Transplant. </span>2005a;<span class="ref-vol">20</span>:1525–9.</span> [<a href="/pubmed/15956068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15956068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.2005b.303">Danpure CJ. Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. <span><span class="ref-journal">Am J Nephrol. </span>2005b;<span class="ref-vol">25</span>:303–10.</span> [<a href="/pubmed/15961951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15961951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.1994a.55">Danpure CJ, Birdsey GM, Rumsby G, Lumb MJ, Purdue PE, Allsop J. Molecular characterization and clinical use of a polymorphic tandem repeat in an intron of the human alanine:glyoxylate aminotransferase gene. <span><span class="ref-journal">Hum Genet. </span>1994a;<span class="ref-vol">94</span>:55–64.</span> [<a href="/pubmed/8034295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8034295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.1994b.487">Danpure CJ, Jennings PR, Fryer P, Purdue PE, Allsop J. Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity. <span><span class="ref-journal">J Inherit Metab Dis. </span>1994b;<span class="ref-vol">17</span>:487–99.</span> [<a href="/pubmed/7967498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7967498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.1989.271">Danpure CJ, Jennings PR, Penketh RJ, Wise PJ, Cooper PJ, Rodeck CH. Fetal liver alanine: glyoxylate aminotransferase and the prenatal diagnosis of primary hyperoxaluria type 1. <span><span class="ref-journal">Prenat Diagn. </span>1989;<span class="ref-vol">9</span>:271–81.</span> [<a href="/pubmed/2717533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2717533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.1993.417">Danpure CJ, Purdue PE, Fryer P, Griffiths S, Allsop J, Lumb MJ, Guttridge KM, Jennings PR, Scheinman JI, Mauer SM, Davidson NO. Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation. <span><span class="ref-journal">Am J Hum Genet. </span>1993;<span class="ref-vol">53</span>:417–32.</span> [<a href="/pmc/articles/PMC1682352/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1682352</span></a>] [<a href="/pubmed/8101040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8101040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.danpure.2004.1">Danpure CJ, Rumsby G. Molecular aetiology of primary hyperoxaluria and its implications for clinical management. <span><span class="ref-journal">Expert Rev Mol Med. </span>2004;<span class="ref-vol">6</span>:1–16.</span> [<a href="/pubmed/14987413" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14987413</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.daudon.2008.100">Daudon M, Jungers P, Bazin D. Peculiar morphology of stones in primary hyperoxaluria. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>:100–2.</span> [<a href="/pubmed/18596285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18596285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.djordjevic.2010.233">Djordjevic S, Zhang X, Bartlam M, Ye S, Rao Z, Danpure CJ. Structural implications of a G170R mutation of alanine:glyoxylate aminotransferase that is associated with peroxisome-to-mitochondrion mistargeting. <span><span class="ref-journal">Acta Crystallogr Sect F Struct Biol Cryst Commun. </span>2010;<span class="ref-vol">66</span>:233–6.</span> [<a href="/pmc/articles/PMC2833026/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2833026</span></a>] [<a href="/pubmed/20208150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20208150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.duffey.2008.1145">Duffey BG, Pedro RN, Makhlouf A, Kriedberg C, Stessman M, Hinck B, Ikramuddin S, Kellogg T, Slusarek B, Monga M. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. <span><span class="ref-journal">J Am Coll Surg. </span>2008;<span class="ref-vol">206</span>:1145–53.</span> [<a href="/pubmed/18501812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18501812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.dutta.2016.770">Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C. Inhibition of glycolate oxidase with dicer substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1. <span><span class="ref-journal">Mol Ther. </span>2016;<span class="ref-vol">24</span>:770–8.</span> [<a href="/pmc/articles/PMC4886950/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4886950</span></a>] [<a href="/pubmed/26758691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26758691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.edvardsson.2013.1923">Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Auglani F, Milliner DS, Palsson R. Hereditary causes of kidney stones and chronic kidney disease. <span><span class="ref-journal">Pediatr Nephrol. </span>2013;<span class="ref-vol">28</span>:1923–42.</span> [<a href="/pmc/articles/PMC4138059/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4138059</span></a>] [<a href="/pubmed/23334384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23334384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.fargue.2009.767">Fargue S, Harambat J, Gagnadoux M-F, Tsimaratos M, Janssen F, Llanas B, Bertheleme J-P, Boudailliez B, Champion G, Guyot G, Macher M-Q, Nivet H, Ranchin B, Salomon R, Taque S, Rolland M-O, Cochat P. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. <span><span class="ref-journal">Kidney Int. </span>2009;<span class="ref-vol">76</span>:767–73.</span> [<a href="/pubmed/19571789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19571789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.fargue.2013a.2475">Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. <span><span class="ref-journal">J Biol Chem. </span>2013a;<span class="ref-vol">288</span>:2475–84.</span> [<a href="/pmc/articles/PMC3554916/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3554916</span></a>] [<a href="/pubmed/23229545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23229545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.fargue.2018.1615">Fargue S, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP. Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria. <span><span class="ref-journal">J Am Soc Nephrol. </span>2018;<span class="ref-vol">29</span>:1615–23.</span> [<a href="/pmc/articles/PMC6054332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6054332</span></a>] [<a href="/pubmed/29588429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29588429</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.fargue.2013b.1776">Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. <span><span class="ref-journal">Biochim Biophys Acta. </span>2013b;<span class="ref-vol">1832</span>:1776–83.</span> [<a href="/pubmed/23597595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23597595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.frishberg.2005.269">Frishberg Y, Rinat C, Shalata A, Khatib I, Feinstein S, Becker-Cohen R, Weismann I, Wanders RJ, Rumsby G, Roels F, Mandel H. Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. <span><span class="ref-journal">Am J Nephrol. </span>2005;<span class="ref-vol">25</span>:269–75.</span> [<a href="/pubmed/15961946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15961946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.fodor.2012.e1001309">Fodor K, Wolf J, Erdmann R, Schliebs W, Wilmanns M. Molecular requirements for peroxisomal targeting of alanine-glyoxylate aminotransferase as an essential determinant in primary hyperoxaluria type 1. <span><span class="ref-journal">PLoS Biol. </span>2012;<span class="ref-vol">10</span>:e1001309.</span> [<a href="/pmc/articles/PMC3328432/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3328432</span></a>] [<a href="/pubmed/22529745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22529745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.getting.2013.768">Getting JE, Gregoire JR, Phul A, Kasten MJ. Oxalate nephropathy due to &#x02018;juicing': case report and review. <span><span class="ref-journal">Am J Med. </span>2013;<span class="ref-vol">126</span>:768–72.</span> [<a href="/pubmed/23830537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23830537</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.grujic.2009.86">Grujic D, Salido EC, Shenoy BC, Langman CB, McGrath ME, Patel RJ, Rashid A, Mandapati S, Jung CW, Margolin AL. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. <span><span class="ref-journal">Am J Nephrol. </span>2009;<span class="ref-vol">29</span>:86–93.</span> [<a href="/pubmed/18698135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18698135</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.guha.2005.161">Guha C, Yamanouchi K, Jiang J, Wang X, Roy Chowdhury N, Santana A, Shapiro LJ, Salido E, Roy-Chowdhury J. Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. <span><span class="ref-journal">Am J Nephrol. </span>2005;<span class="ref-vol">25</span>:161–70.</span> [<a href="/pubmed/15849463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15849463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.harambat.2010.443">Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, Mourani C, Macher MA, Abramowicz D, Legendre C, Durrbach A, Tsimaratos M, Nivet H, Girardin E, Schott AM, Rolland MO, Cochat P. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. <span><span class="ref-journal">Kidney Int. </span>2010;<span class="ref-vol">77</span>:443–9.</span> [<a href="/pubmed/20016466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20016466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.harambat.2011.864580">Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. <span><span class="ref-journal">Int J Nephrol. </span>2011;<span class="ref-vol">2011</span>:864580.</span> [<a href="/pmc/articles/PMC3124893/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3124893</span></a>] [<a href="/pubmed/21748001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21748001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.harambat.2012.458">Harambat J, van Stralen KJ, Espinosa L, Groothoff JQ, Hulton SA, Cerkausiene R, Schaefer F, Verrina E, Jager KJ, Cochat P. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2012;<span class="ref-vol">7</span>:458–65.</span> [<a href="/pmc/articles/PMC3302673/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3302673</span></a>] [<a href="/pubmed/22223608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22223608</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hatch.2006.691">Hatch M, Cornelius J, Sidhu H, Peck A, Freel RW. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. <span><span class="ref-journal">Kidney Int. </span>2006;<span class="ref-vol">69</span>:691–8.</span> [<a href="/pubmed/16518326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16518326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hatch.2013.379">Hatch M., Freel RW. A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. <span><span class="ref-journal">Urolithiasis. </span>2013;<span class="ref-vol">41</span>:379–84.</span> [<a href="/pmc/articles/PMC3815490/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3815490</span></a>] [<a href="/pubmed/23959075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23959075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hatch.2008.143">Hatch M, Freel RW. The roles and mechanisms of intestinal oxalate transport in oxalate homeostasis. <span><span class="ref-journal">Semin Nephrol. </span>2008;<span class="ref-vol">28</span>:143–51.</span> [<a href="/pmc/articles/PMC2430047/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2430047</span></a>] [<a href="/pubmed/18359395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18359395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hern_ndezfernaud.2010.4766">Hern&#x000e1;ndez-Fernaud JR, Salido E. Differential expression of liver and kidney proteins in a mouse model for primary hyperoxaluria type 1. <span><span class="ref-journal">FEBS Journal. </span>2010;<span class="ref-vol">277</span>:4766–74.</span> [<a href="/pubmed/20977670" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20977670</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.holmes.1998.1617">Holmes RP, Assimos DG. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. <span><span class="ref-journal">J Urol. </span>1998;<span class="ref-vol">160</span>:1617–24.</span> [<a href="/pubmed/9783918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9783918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.holmes.2001a.858">Holmes RP, Assimos DG, Wilson DM, Milliner DS. (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1. <span><span class="ref-journal">BJU Int. </span>2001a;<span class="ref-vol">88</span>:858–62.</span> [<a href="/pubmed/11851603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11851603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.holmes.2004.311">Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. <span><span class="ref-journal">Urol Res. </span>2004;<span class="ref-vol">32</span>:311–6.</span> [<a href="/pubmed/15221245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15221245</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.holmes.2000.1662">Holmes RP, Kennedy M. Estimation of the oxalate content of foods and daily oxalate intake. <span><span class="ref-journal">Kidney Int. </span>2000;<span class="ref-vol">57</span>:1662–7.</span> [<a href="/pubmed/10760101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10760101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.holmes.2001b.270">Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. <span><span class="ref-journal">Kidney Int. </span>2001b;<span class="ref-vol">59</span>:270–6.</span> [<a href="/pubmed/11135080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11135080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hopp.2015.2559">Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC., Rare Kidney Stone Consortium.  Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. <span><span class="ref-journal">J Am Soc Nephrol. </span>2015;<span class="ref-vol">26</span>:2559–70.</span> [<a href="/pmc/articles/PMC4587693/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4587693</span></a>] [<a href="/pubmed/25644115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25644115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoppe.2012.467">Hoppe B. An update on primary hyperoxaluria. <span><span class="ref-journal">Nat Rev Nephrol. </span>2012;<span class="ref-vol">8</span>:467–75.</span> [<a href="/pubmed/22688746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22688746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoppe.2006.1305">Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H. Oxalobacter formingenes: a potential tool for the treatment of primary hyperoxaluria type 1. <span><span class="ref-journal">Kidney Int. </span>2006;<span class="ref-vol">70</span>:1305–11.</span> [<a href="/pubmed/16850020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16850020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoppe.2009.1264">Hoppe B, Beck B, Milliner DS. The primary hyperoxalurias. <span><span class="ref-journal">Kidney Int. </span>2009;<span class="ref-vol">75</span>:1264–71.</span> [<a href="/pmc/articles/PMC4577278/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4577278</span></a>] [<a href="/pubmed/19225556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19225556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoppe.1997.36">Hoppe B, Danpure CJ, Rumsby G, Fryer P, Jennings PR, Blau N, Schubiger G, Neuhaus T, Leumann E. A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity. <span><span class="ref-journal">Am J Kidney Dis. </span>1997;<span class="ref-vol">29</span>:36–44.</span> [<a href="/pubmed/9002528" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9002528</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoppe.2011.3609">Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2011;<span class="ref-vol">26</span>:3609–15.</span> [<a href="/pubmed/21460356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21460356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoppe.2017.781">Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van&#x02019;t Hoff W, Moochhal SH, Desch&#x000ea;nes G, Lindner E, Sj&#x000f6;gren A, Cochat P. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered <em>Oxalobacter formigenes</em> to treat primary hyperoxaluria. <span><span class="ref-journal">Pediatr Nephrol. </span>2017;<span class="ref-vol">32</span>:781–90.</span> [<a href="/pubmed/27924398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27924398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hopper.2008.30493">Hopper ED, Pittman A, Fitzgerald M, Tucker C. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase. <span><span class="ref-journal">J Biol Chem. </span>2008;<span class="ref-vol">283</span>:30493–502.</span> [<a href="/pmc/articles/PMC2576547/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2576547</span></a>] [<a href="/pubmed/18782763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18782763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.hoyerkuhn.2014.468">Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Beck BB, Hoppe B. Vitamin B6 in primary hyperoxaluria 1: first prospective trial after 40 years of practice. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2014;<span class="ref-vol">9</span>:468–77.</span> [<a href="/pmc/articles/PMC3944765/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3944765</span></a>] [<a href="/pubmed/24385516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24385516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.ivanovski.2013.998">Ivanovski O, Dr&#x000fc;eke TB. A new era in the treatment of calcium oxalate stones? <span><span class="ref-journal">Kidney Int. </span>2013;<span class="ref-vol">83</span>:998–1000.</span> [<a href="/pubmed/23728004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23728004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.jiang.2008.1253">Jiang J, Salido EC, Guha C, Wang X, Moitra R, Liu L, Roy-Chowdhury J, Roy-Chowdhury N. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type1. <span><span class="ref-journal">Transplantation. </span>2008;<span class="ref-vol">85</span>:1253–60.</span> [<a href="/pubmed/18475180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18475180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.kamoun.1996.479">Kamoun A, Lakhoua R. End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome. <span><span class="ref-journal">Pediatr Nephrol. </span>1996;<span class="ref-vol">10</span>:479–82.</span> [<a href="/pubmed/8865247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8865247</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.kleinman.2007.8">Kleinman JG. Bariatric surgery, hyperoxaluria, and nephrolithiasis: a plea for close postoperative management of risk factors. <span><span class="ref-journal">Kidney Int. </span>2007;<span class="ref-vol">72</span>:8–10.</span> [<a href="/pubmed/17597787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17597787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.knight.2012.f688">Knight J, Holmes RP, Cramer SD, Takayama T, Salido E. Hydroxyproline metabolism in mouse models of primary hyperoxaluria. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2012;<span class="ref-vol">302</span>:F688–93.</span> [<a href="/pmc/articles/PMC3311317/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3311317</span></a>] [<a href="/pubmed/22189945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22189945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.koul.2005.176">Koul S, Johnson T, Pramanik S, Koul H. Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1). <span><span class="ref-journal">Am J Nephrol. </span>2005;<span class="ref-vol">25</span>:176–82.</span> [<a href="/pmc/articles/PMC1242120/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1242120</span></a>] [<a href="/pubmed/15849465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15849465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.kumar.2011.654">Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, Bergstralh EJ, Li X. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. <span><span class="ref-journal">Surgery. </span>2011;<span class="ref-vol">149</span>:654–61.</span> [<a href="/pmc/articles/PMC3078956/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3078956</span></a>] [<a href="/pubmed/21295813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21295813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.leumann.1990.493">Leumann EP, Dietl A, Matasovic A. Urinary oxalate and glycolate excretion in healthy infants and children. <span><span class="ref-journal">Pediatr Nephrol. </span>1990;<span class="ref-vol">4</span>:493–7.</span> [<a href="/pubmed/2242313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2242313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.lieske.2008.163">Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. <span><span class="ref-journal">Semin Nephrol. </span>2008;<span class="ref-vol">28</span>:163–73.</span> [<a href="/pmc/articles/PMC2831413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2831413</span></a>] [<a href="/pubmed/18359397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18359397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.lorenzo.2006.1115">Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hernandez D, Salido E. Presentation and role of transplantation in adult patients with type 1 primary hyper&#x000ac;oxaluria and the I244T AGXT mutation: single-centre experience. <span><span class="ref-journal">Kidney Int. </span>2006;<span class="ref-vol">70</span>:1115–9.</span> [<a href="/pubmed/16912707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16912707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.lumb.2000.36415">Lumb MJ, Danpure CJ. Functional synergism between the most common polymorphism in human alanine: glyoxylate aminotransferase and four of the most common disease-causing mutations. <span><span class="ref-journal">J Biol Chem. </span>2000;<span class="ref-vol">275</span>:36415–22.</span> [<a href="/pubmed/10960483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10960483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.lumb.1999.20587">Lumb MJ, Drake AF, Danpure CJ. Effect of N-terminal alpha-helix formation on the dimerization and intracellular targeting of alanine:glyoxylate aminotransferase. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:20587–96.</span> [<a href="/pubmed/10400689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10400689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.luyckx.2005.s68">Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. <span><span class="ref-journal">Kidney Int Suppl. </span>2005;<span class="ref-vol">97</span>:S68–77.</span> [<a href="/pubmed/16014104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16014104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.luyckx.2010.898">Luyckx VA, Brenner BM. The Clinical Importance of Nephron Mass. <span><span class="ref-journal">J Am Soc Nephrol. </span>2010;<span class="ref-vol">21</span>:898–910.</span> [<a href="/pubmed/20150537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20150537</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.madani.2001.140">Madani K, Otoukesh H, Rastegar A, Van Why S. Chronic renal failure in Iranian children. <span><span class="ref-journal">Pediatr Nephrol. </span>2001;<span class="ref-vol">16</span>:140–4.</span> [<a href="/pubmed/11261681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11261681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.mandrile.2008.309">Mandrile G, Robbiano A, Giachino D, Sebastriano R, Dondi E, Fenoglio R, Stratta P, Caruso M, Petrarulo M, Marangella M, De Marchi M. Primary hyperoxaluira: report of an Italian family with clear sex conditioned penetrance. <span><span class="ref-journal">Urol Res. </span>2008;<span class="ref-vol">36</span>:309–12.</span> [<a href="/pubmed/18985333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18985333</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.mandrile.2014.1197">Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G. OxalEurope Consortium. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. <span><span class="ref-journal">Kidney Int. </span>2014;<span class="ref-vol">86</span>:1197–204.</span> [<a href="/pubmed/24988064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24988064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.marangella.1995">Marangella M, Petrarulo M. Oxalate measurements in biological fluids. In: Khan SR, ed. <em>Calcium Oxalate in Biological Systems.</em> New York, NY: CRC Press; 1995:239-63.</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.mart_n.2011.227">Mart&#x000ed;n M, Mart&#x000ed;n Reyes G, Torres de Rueda A, Toledo Rojas R, Jironda C, Garc&#x000ed;a I, Garc&#x000ed;a de la Oliva T, P&#x000e9;rez Vaca ML, Hern&#x000e1;ndez D. Delayed diagnosis of primary hyperoxaluria type in a young patient with advanced chronic renal failure. <span><span class="ref-journal">Nefrologia. </span>2011;<span class="ref-vol">31</span>:227–9.</span> [<a href="/pubmed/21461022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21461022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.martinhigueras.2016.719">Martin-Higueras C, Luis-Lima S, Salido E. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I. <span><span class="ref-journal">Mol Ther. </span>2016;<span class="ref-vol">24</span>:719–25.</span> [<a href="/pmc/articles/PMC4886931/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4886931</span></a>] [<a href="/pubmed/26689264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26689264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.mashour.2000.561">Mashour S, Turner JF Jr, Merrell R. Acute renal failure, oxalosis, and vitamin C supplementation: a case report and review of the literature. <span><span class="ref-journal">Chest. </span>2000;<span class="ref-vol">118</span>:561–3.</span> [<a href="/pubmed/10936161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10936161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.mesatorres.2013.e71963">Mesa-Torres N, Fabelo-Rosa I, Riverol D, Yunta C, Albert A, Salido E, Pey AL. The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e71963.</span> [<a href="/pmc/articles/PMC3796444/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3796444</span></a>] [<a href="/pubmed/24205397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24205397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.millan.2003.1458">Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. <span><span class="ref-journal">Transplantation. </span>2003;<span class="ref-vol">76</span>:1458–63.</span> [<a href="/pubmed/14657686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14657686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.milliner.2016.666">Milliner DS. siRNA therapeutics for primary hyperoxaluria: a beginning. <span><span class="ref-journal">Mol Ther. </span>2016;<span class="ref-vol">24</span>:666–7.</span> [<a href="/pmc/articles/PMC4886951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4886951</span></a>] [<a href="/pubmed/27081720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27081720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.milliner.2006.27">Milliner DS. Stones, bones, and heredity. <span><span class="ref-journal">Acta Paediatr Suppl. </span>2006;<span class="ref-vol">95</span>:27–30.</span> [<a href="/pubmed/16801162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16801162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.milliner.2005.154">Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. <span><span class="ref-journal">Am J Nephrol. </span>2005;<span class="ref-vol">25</span>:154–60.</span> [<a href="/pubmed/15855742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15855742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.milliner.2018.313">Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. <span><span class="ref-journal">Urolithiasis. </span>2018;<span class="ref-vol">46</span>:313–23.</span> [<a href="/pmc/articles/PMC6061479/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6061479</span></a>] [<a href="/pubmed/28718073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28718073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.mitsimponas.2012.e301">Mitsimponas KT, Wehrhan T, Falk S, Wehrhan R, Neukam FW, Schlegel KA. Oral findings associated with primary hyperoxaluria type 1. <span><span class="ref-journal">J Craniomaxillofac Surg. </span>2012;<span class="ref-vol">40</span>:e301–6.</span> [<a href="/pubmed/22417769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22417769</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.miyata.2014.14406">Miyata N, Steffen J, Johnson ME, Fargue S, Danpure CJ, Koehler CM. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2014;<span class="ref-vol">111</span>:14406–11.</span> [<a href="/pmc/articles/PMC4210028/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4210028</span></a>] [<a href="/pubmed/25237136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25237136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.monico.2001.954">Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. <span><span class="ref-journal">Liver Transpl. </span>2001;<span class="ref-vol">7</span>:954–63.</span> [<a href="/pubmed/11699031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11699031</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.monico.2011.151">Monico CG, Milliner DS. Genetic determinants of urolithiasis. <span><span class="ref-journal">Nat Rev Nephrol. </span>2011;<span class="ref-vol">8</span>:151–62.</span> [<a href="/pmc/articles/PMC3901084/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3901084</span></a>] [<a href="/pubmed/22183508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22183508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.monico.2005a.183">Monico CG, Olson JB, Milliner DS. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. <span><span class="ref-journal">Am J Nephrol. </span>2005a;<span class="ref-vol">25</span>:183–8.</span> [<a href="/pubmed/15849466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15849466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.monico.2005b.1704">Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. <span><span class="ref-journal">Kidney Int. </span>2005b;<span class="ref-vol">67</span>:1704–9.</span> [<a href="/pubmed/15840016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15840016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.monico.2007.1905">Monico CG, Rossetti S, Schwanz HA, Olson J, Lundquist P, Dawson D, Harris P, Milliner DS. Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibiity of a gene-based diagnosis. <span><span class="ref-journal">J Am Soc Nephrol. </span>2007;<span class="ref-vol">18</span>:1905–14.</span> [<a href="/pubmed/17460142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17460142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.monk.2000">Monk RD, Bushinsky DA. Nephrolithiasis and nephrocalcinosis. In: Johnson RJ, Feehally J, eds. <em>Comprehensive Clinical Nephrology.</em> London: Mosby; 2000:12731-44.</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.nishiyama.1993.1237">Nishiyama K, Funai T, Yokota S, Ichiyama A. ATP-dependent degradation of a mutant serine: pyruvate/alanine:glyoxylate aminotransferase in a primary hyperoxaluria type 1 case. <span><span class="ref-journal">J Cell Biol. </span>1993;<span class="ref-vol">123</span>:1237–48.</span> [<a href="/pmc/articles/PMC2119878/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2119878</span></a>] [<a href="/pubmed/8245128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8245128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.nogueira.2000.384">Nogueira PK, Vuong TS, Bouton O, Maillard A, Marchand M, Rolland MO, Cochat P, Bozon D. Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1. <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">15</span>:384–5.</span> [<a href="/pubmed/10737993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10737993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.norby.2004.277">Norby SM, Milliner DS. Outcomes and complications of pregnancy in women with primary hyperoxaluria. <span><span class="ref-journal">Am J Kidney Dis. </span>2004;<span class="ref-vol">43</span>:277–85.</span> [<a href="/pubmed/14750093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14750093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.oppici.2015.5500">Oppici E, Fargue S, Reid ES, Mills PB, Clayton PT, Danpure CJ, Cellini B. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: glyoxylate aminotransferase causing primary hyperoxaluria type I. <span><span class="ref-journal">Hum Mol Genet. </span>2015;<span class="ref-vol">24</span>:5500–11.</span> [<a href="/pubmed/26199318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26199318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.oppici.2012.132">Oppici E, Montioli R, Lorenzetto A, Bianconi S, Borri Voltattorni C, Cellini B. Biochemical analyses are instrumental in identifying the impact of mutations on holo and/or apo-forms and on the region(s) of alanine:glyoxylate aminotransferase variants associated with primary hyperoxaluria type I. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:132–40.</span> [<a href="/pmc/articles/PMC3271384/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3271384</span></a>] [<a href="/pubmed/22018727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22018727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.pace.2000.1905">Pace KT, Weir MJ, Tariq N, Honey RJ. Low success rate of repeat shock wave lithotripsy for ureteral stones after failed initial treatment. <span><span class="ref-journal">J Urol. </span>2000;<span class="ref-vol">164</span>:1905–7.</span> [<a href="/pubmed/11061877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11061877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.pey.2013.687658">Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. <span><span class="ref-journal">Biomed Res Int. </span>2013;<span class="ref-vol">2013</span>:687658.</span> [<a href="/pmc/articles/PMC3730394/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3730394</span></a>] [<a href="/pubmed/23956997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23956997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.penniston.2009.484">Penniston KL, Nakada SY. Effects of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation. <span><span class="ref-journal">Urology. </span>2009;<span class="ref-vol">73</span>:484–9.</span> [<a href="/pubmed/19118878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19118878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.perinpam.2017.1014">Perinpam M, Enders FT, Mara KC, Vaughan LE, Mehta RA, Voskoboev N, Milliner DS, Lieske JC. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. <span><span class="ref-journal">Clin Biochem. </span>2017;<span class="ref-vol">50</span>:1014–9.</span> [<a href="/pmc/articles/PMC5705406/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5705406</span></a>] [<a href="/pubmed/28764885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28764885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.petrarulo.1998.23">Petrarulo M, Vitale C, Facchini P, Marangella M. Biochemical approach to diagnosis and differentiation of primary hyperoxalurias: an update. <span><span class="ref-journal">J Nephrol. </span>1998;<span class="ref-vol">11</span>:23–8.</span> [<a href="/pubmed/9604805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9604805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.pirulli.2003.297">Pirulli D, Marangella M, Amoroso A. Primary hyperoxaluria: genotype-phenotype correlation. <span><span class="ref-journal">J Nephrol. </span>2003;<span class="ref-vol">16</span>:297–309.</span> [<a href="/pubmed/12768081" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12768081</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.plumb.2013.1155">Plumb TJ, Swee ML, Fillaus JA. Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. <span><span class="ref-journal">Am J Kidney Dis. </span>2013;<span class="ref-vol">62</span>:1155–9.</span> [<a href="/pubmed/23830800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23830800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.pruvot.1997.615">Pruvot FR, Noel C, Declerck N, Valat-Rigot AS, Roumilhac D, Hazzan M, Puech F, Lelievre G. Consecutive successful pregnancies in a combined liver and kidney transplant recipient with type 1 primary hyperoxaluria. <span><span class="ref-journal">Transplantation. </span>1997;<span class="ref-vol">63</span>:615–6.</span> [<a href="/pubmed/9047162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9047162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.puddu.2009.162">Puddu M, Fanos V, Podda F, Zaffanello M. The kidney from prenatal to adult life: perinatal programming and reduction of number of nephrons during development. <span><span class="ref-journal">Am J Nephrol. </span>2009;<span class="ref-vol">30</span>:162–70.</span> [<a href="/pubmed/19339773" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19339773</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.purdue.1991.10900">Purdue PE, Allsop J, Isaya G, Rosenberg LE, Danpure CJ. Mistargeting of peroxisomal L-alanine:glyoxylate aminotransferase to mitochondria in primary hyperoxaluria patients depends upon activation of a cryptic mitochondrial targeting sequence by a point mutation. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1991;<span class="ref-vol">88</span>:10900–4.</span> [<a href="/pmc/articles/PMC53039/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC53039</span></a>] [<a href="/pubmed/1961759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1961759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.quigley.2012.184">Quigley R. Developmental changes in renal function. <span><span class="ref-journal">Curr Opin Pediatr. </span>2012;<span class="ref-vol">24</span>:184–90.</span> [<a href="/pubmed/22426155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22426155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.rao.2014.411">Rao NM, Yallapragada A, Winden KD, Saver J, Liebeskind DS. Stroke in primary hyperoxaluria type I. <span><span class="ref-journal">J Neuroimaging. </span>2014;<span class="ref-vol">24</span>:411–3.</span> [<a href="/pmc/articles/PMC4156598/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4156598</span></a>] [<a href="/pubmed/23551880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23551880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.remer.2002.561">Remer T, Neubert A, Maser-Gluth C. Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. <span><span class="ref-journal">Am J Clin Nutr. </span>2002;<span class="ref-vol">75</span>:561–9.</span> [<a href="/pubmed/11864864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11864864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.rinat.1999.2352">Rinat C, Wanders RJ, Drukker A, Halle D, Frishberg Y. Primary hyperoxaluria type I: a model for multiple mutations in a monogenic disease within a distinct ethnic group. <span><span class="ref-journal">J Am Soc Nephrol. </span>1999;<span class="ref-vol">10</span>:2352–8.</span> [<a href="/pubmed/10541294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10541294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.robbiano.2010.667">Robbiano A, Frecer V, Miertus J, Zadro C, Ulivi S, Bevilacqua E, Mandrile G, De Marchi M, Miertus S, Amoroso A. Modeling the effect of 3 missense <em>AGXT</em> mutations on the dimerization of the AGT enzyme in primary hyperoxaluria type 1. <span><span class="ref-journal">J Nephrol. </span>2010;<span class="ref-vol">23</span>:667–76.</span> [<a href="/pubmed/20564000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20564000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.roncador.2017.897">Roncador A, Oppici E, Talelli M, Pariente AN, Donini M, Dusi S, Voltattorni CB, Vicent MJ, Cellini B. Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine: glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I. <span><span class="ref-journal">Nanomedicine. </span>2017;<span class="ref-vol">13</span>:897–907.</span> [<a href="/pubmed/27993722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27993722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.rumsby.2001.1697">Rumsby G, Sharma A, Cregeen DP, Solomon LR. Primary hyperoxaluria type 2 without L-glycericaciduria: is the disease under-diagnosed? <span><span class="ref-journal">Nephrol Dial Transplant. </span>2001;<span class="ref-vol">16</span>:1697–9.</span> [<a href="/pubmed/11477177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11477177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.salido.2011.870">Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. <span><span class="ref-journal">Mol Ther. </span>2011;<span class="ref-vol">19</span>:870–5.</span> [<a href="/pmc/articles/PMC3098628/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3098628</span></a>] [<a href="/pubmed/21119625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21119625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.santana.2003.7277">Santana A, Salido E, Torres A, Shapiro LJ. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2003;<span class="ref-vol">100</span>:7277–82.</span> [<a href="/pmc/articles/PMC165866/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC165866</span></a>] [<a href="/pubmed/12777626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12777626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.scheinman.2005.368">Scheinman JI, Voziyan PA, Belmont JM, Chetyrkin SV, Kim D, Hudson BG. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. <span><span class="ref-journal">Urol Res. </span>2005;<span class="ref-vol">33</span>:368–71.</span> [<a href="/pubmed/16292584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16292584</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.semins.2010.826">Semins MJ, Asplin JR, Steele K, Assimos DG, Lingeman JE, Donahue S, Magnuson T, Schweitzer M, Matlaga BR. The effect of restrictive bariatric surgery on urinary stone risk factors. <span><span class="ref-journal">Urology. </span>2010;<span class="ref-vol">76</span>:826–9.</span> [<a href="/pubmed/20381135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20381135</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.sikora.2003.2194">Sikora P, Roth B, Kribs A, Michalk D, Hesse A, Hoppe B. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. <span><span class="ref-journal">Kidney Int. </span>2003;<span class="ref-vol">63</span>:2194–9.</span> [<a href="/pubmed/12753307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12753307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.sikora.2008.1181">Sikora P, Unruh G, Beck B, Feldkotter M, Zajaczkowska M, Hesse A, Hoppe B. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. <span><span class="ref-journal">Kidney Int. </span>2008;<span class="ref-vol">73</span>:1181–6.</span> [<a href="/pubmed/18337715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18337715</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.tammachote.2012.2124">Tammachote R, Kingsuwannapong N, Tongkobpetch S, Srichomthong C, Yeetong P, Kingwatanakul P, Monico CG, Suphapeetiporn K, Shotelersuk V. Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:2124–30.</span> [<a href="/pubmed/22821680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22821680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.tang.2014.376">Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. <span><span class="ref-journal">Am J Nephrol. </span>2014;<span class="ref-vol">39</span>:376–82.</span> [<a href="/pmc/articles/PMC4485608/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4485608</span></a>] [<a href="/pubmed/24776840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24776840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.tarn.1997.689">Tarn AC, von Schnakenburg C, Rumsby G. Primary hyperoxaluria type 1: diagnostic relevance of mutations and polymorphisms in the alanine:glyoxylate aminotransferase gene (AGXT). <span><span class="ref-journal">J Inherit Metab Dis. </span>1997;<span class="ref-vol">20</span>:689–96.</span> [<a href="/pubmed/9323564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9323564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.tasca.2011.129">Tasca A. Metabolic syndrome and bariatric surgery in stone disease etiology. <span><span class="ref-journal">Curr Opin Urol. </span>2011;<span class="ref-vol">21</span>:129–33.</span> [<a href="/pubmed/21191301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21191301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.toussaint.1998.49">Toussaint C. Pyridoxine-responsive PH1: treatment. <span><span class="ref-journal">J Nephrol. </span>1998;<span class="ref-vol">11</span> Suppl 1:49–50.</span> [<a href="/pubmed/9604811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9604811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.trotter.2014.241">Trotter JF, Milliner D. Auxiliary liver transplant is an ineffective treatment of primary hyperoxaluria. <span><span class="ref-journal">Am J Transplant. </span>2014;<span class="ref-vol">14</span>:241.</span> [<a href="/pubmed/24330139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24330139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.van_der_hoeven.2012.3855">van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2012;<span class="ref-vol">27</span>:3855–62.</span> [<a href="/pubmed/22844106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22844106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.van_woerden.2003.273">van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2003;<span class="ref-vol">18</span>:273–9.</span> [<a href="/pubmed/12543880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12543880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.van_woerden.2004.746">van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR. Clinical implications of mutation analysis in primary hyperoxaluria type 1. <span><span class="ref-journal">Kidney Int. </span>2004;<span class="ref-vol">66</span>:746–52.</span> [<a href="/pubmed/15253729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15253729</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.van_woerden.2006.346">van Woerden CS, Groothoff JW, Wijburg FA, Duran M, Wanders RJA, Barth PG, Poll-The BT. High incidence of hyperoxaluria in generalized peroxisomal disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2006;<span class="ref-vol">88</span>:346–50.</span> [<a href="/pubmed/16621644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16621644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.von_schnakenburg.1994.27">von Schnakenburg C, Byrd DJ, Latta K, Reusz GS, Graf D, Brodehl J. Determination of oxalate excretion in spot urines of healthy children by ion chromatography. <span><span class="ref-journal">Eur J Clin Chem Clin Biochem. </span>1994;<span class="ref-vol">32</span>:27–9.</span> [<a href="/pubmed/8167190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8167190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.waters.2001.57">Waters PJ. Degradation of mutant proteins, underlying "loss of function" phenotypes, plays a major role in genetic disease. <span><span class="ref-journal">Curr Issues Mol Biol. </span>2001;<span class="ref-vol">3</span>:57–65.</span> [<a href="/pubmed/11488412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11488412</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.williams.2009.910">Williams EL, Acquaviva A, Chevalier F, Coulter-Mackie B, Monico C, Giachino D, Robbiano A, Salido E, Waterham H, Rumsby G. Primary hyperoxaluria type 1: Update and additional mutation analysis of the AGXT gene. <span><span class="ref-journal">Hum Mut. </span>2009;<span class="ref-vol">30</span>:910–7.</span> [<a href="/pubmed/19479957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19479957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.williams.2007.1216">Williams E, Rumsby G. Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50% of patients with primary hyperoxaluria type 1. <span><span class="ref-journal">Clin Chem. </span>2007;<span class="ref-vol">53</span>:1216–21.</span> [<a href="/pubmed/17495019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17495019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.williams.2003.1092">Williams JC Jr, Saw KC, Paterson RF, Hatt EK, McAteer JA, Lingeman JE. Variability of renal stone fragility in shock wave lithotripsy. <span><span class="ref-journal">Urology. </span>2003;<span class="ref-vol">61</span>:1092–6.</span> [<a href="/pubmed/12809867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12809867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.zapatalinares.2016.116">Zapata-Linares N, Rodriguez S, Salido E, Abizanda G, Iglesias E, Prosper F, Gonzalez-Aseguinolaza G, Rodriguez-Madoz JR. Generation and characterization of human iPSC lines derived from a primary hyperoxaluria type I patient with p.I244T mutation. <span><span class="ref-journal">Stem Cell Res. </span>2016;<span class="ref-vol">16</span>:116–9.</span> [<a href="/pubmed/27345794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27345794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.zhang.2003.643">Zhang X, Roe SM, Hou Y, Bartlam M, Rao Z, Pearl LH, Danpure CJ. Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. <span><span class="ref-journal">J Mol Biol. </span>2003;<span class="ref-vol">331</span>:643–52.</span> [<a href="/pubmed/12899834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12899834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ph1.REF.zhao.2016.119">Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS., Investigators of Rare Kidney Stone Consortium.  Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2016;<span class="ref-vol">11</span>:119–26.</span> [<a href="/pmc/articles/PMC4702224/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4702224</span></a>] [<a href="/pubmed/26656319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656319</span></a>]</div></li></ul></div></div><div id="ph1.Chapter_Notes"><h2 id="_ph1_Chapter_Notes_">Chapter Notes</h2><div id="ph1.Author_History"><h3>Author History</h3><p>Ben H Chew, MD, MSc, FRCSC; University of British Columbia (2009-2017)<br />Andrea G Cogal (2017-present)<br />Marion B Coulter-Mackie, PhD; BC Children's Hospital and BC Women's Hospital &#x00026; Health Centre (2002-2017)<br />Peter C Harris, PhD (2017-present)<br />R Morrison Hurley, MD, MSc, FRCPC; BC Children's Hospital (2002-2014)<br />Dirk Lange, PhD; University of British Columbia (2009-2017)<br />John C Lieske, MD (2017-present)<br />Dawn S Milliner, MD (2017-present)<br />Colin T White, MD; BC Children's Hospital and BC Women's Hospital &#x00026; Health Centre (2002-2017)</p></div><div id="ph1.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>30 November 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 July 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 November 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 August 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 December 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 June 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 June 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>4 January 2002 (rmh) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1283</span><span class="label">PMID: <a href="/pubmed/20301460" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301460</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bgc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ph2/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1283&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1283/?report=reader">PubReader</a></li><li><a href="/books/NBK1283/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1283" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1283" style="display:none" title="Cite this Page"><div class="bk_tt">Milliner DS, Harris PC, Cogal AG, et al. Primary Hyperoxaluria Type 1. 2002 Jun 19 [Updated 2017 Nov 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1283/pdf/Bookshelf_NBK1283.pdf">PDF version of this page</a> (713K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ph1.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ph1.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ph1.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ph1.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ph1.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ph1.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ph1.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ph1.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ph1.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ph1.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ph1.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=189[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AGXT</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1487876" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1487876" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1487876" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1487876" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301742" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rumsby G, Hulton SA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26401545" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 3</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Primary Hyperoxaluria Type 3<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Milliner DS, Harris PC, Lieske JC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301501" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sweeney WE, Avner ED. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26380104" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.</a><span class="source">[Can J Kidney Health Dis. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bollée G, Cochat P, Daudon M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Can J Kidney Health Dis. 2015; 2:31. Epub 2015 Sep 15.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30676254" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.</a><span class="source">[Nucleic Acid Ther. 2019]</span><div class="brieflinkpop offscreen_noflow">Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kukreja A, Lasaro M, Cobaugh C, Forbes C, Tang JP, Gao X, Martin-Higueras C, Pey AL, Salido E, Sobolov S, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nucleic Acid Ther. 2019 Apr; 29(2):104-113. Epub 2019 Jan 24.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301460" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301460" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0418a6dd21425a254441bf">Primary Hyperoxaluria Type 1 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Primary Hyperoxaluria Type 1 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:19:18-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE893893E040873100000000081C038A&amp;ncbi_session=CE893893E0418A51_2076SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1283%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1283&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1283/&amp;ncbi_pagename=Primary Hyperoxaluria Type 1 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE893893E0418A51_2076SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>